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Cyclic nucleotide hydrolysis by phosphodiesterases (PDEs) is an important process
determining the amplitude and duration of the responses to cyclic nucleotide
generating agonists. In adenohypophysial corticotrophs and mouse pituitary
corticotroph tumour AtT20 cells, ACTH secretion is known to be mediated by the
cyclic adenosine-3,5-monophosphate (cAMP) pathway. The aim of this thesis is to
identify the cAMP-hydrolysing phosphodiesterase isozymes expressed in rat
adenohypophysis and AtT20 cells. In addition, the regulation of their activities by
cAMP-dependent pathway in AtT20 cells will be studied.
Combination of biochemical, pharmacological and molecular biological methods of
analysis showed that Ca2+/calmodulin (CaM)-stimulated (PDE1) and cAMP-specific,
rolipram-inhibitable (PDE4) PDE isotypes are expressed in AtT20 cells as well as rat
adenohypophysis. Kinetic studies indicated that both rat adenohypophysis and
AtT20 cells contain low- and high-Km PDE1 activities. RT-PCR analysis revealed
the expression of mRNAs from the PDE IB, PDE1C, PDE4A, PDE4B and PDE4D
subfamilies in AtT20 cells and PDE1C, PDE4B and PDE4D in rat adenohypophysis.
Stimulation of the cAMP pathway in AtT20 cells was found to increase the PDE4
activity and reduce that of PDE 1. Calyculin A, an inhibitor of protein phosphatase 1
and 2A, had an additive effect on PDE4 activation by CPT-cAMP and synergistically
enhanced the inhibition of PDE1 by CPT-cAMP. Incubation of AtT20 cytosol with
the catalytic subunit of PKA produced the same changes of PDE1 and PDE4
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activities as the activation of PKA in intact cells. The reduction of PDE1 activity
was associated with a markedly diminished response to stimulation by Ca2+/CaM.
Immunoprecipitation studies with isozyme-specific antibodies showed that PDE4D
isozymes accounted for more than half of the control as well as CPT-cAMP and/or
calyculin A activated PDE4 activity in AtT20 cells. Immunoblot analysis of the
immunoprecipitate showed two distinct bands which, on the basis of their respective
molecular weights, corresponded to splice variants, PDE4D3 and PDE4D5. The
migration of both bands in SDS-PAGE was retarded upon CPT-cAMP and/or
calyculin A treatments, indicative of covalent modification by phosphorylation.
In sum, these data indicate that 1) Splice variants derived from multiple PDE1 and
PDE4 genes are expressed in rat adenohypophysis as well as AtT20 cells 2) Low Km
PDE1, plausibly PDE1C, is found in rat adenohypophysis and AtT20 cells 3) The
rapid and differential regulation of PDE1 and PDE4 by cAMP-dependent
phosphorylation and dephosphorylation in AtT20 cells may provide a mechanism for
fine tuning the Ca2+/CaM-dependency and the extent of cAMP hydrolysis in relation
9+ • i •
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1.1 Intracellular Signal Transduction
The integrity and survival of an organism in a changing environment depend on the
ability of the cells to perceive and respond to the changes, which can be either
physical (e.g. light, electricity, pressure and temperature) or chemical (food,
hormones and neurotransmitters). Extracellular signals are perceived through
proteins known as receptors that are usually located on the cell surface but are also
found within the cell. Upon perception of extracellular signals by their respective
specific receptors, a diverse range of intracellular signalling components is involved
to transduce these signals into and within the cell to produce the appropriate response
through the modulation of intracellular protein functions and gene expression. The
involvement of different signalling components and their sequence in the signal
transduction cascades induced by different extracellular stimuli were found to
constitute distinct signal transduction pathways. In addition to protein
phosphorylation and dephosphorylation on serine, threonine or tyrosine residues,
which are among the most common and important regulatory mechanisms in signal
transduction [1, 2], many signalling pathways involved the generation of an
intracellular second messenger (in response to the extracellular stimulus or the first
9+
messenger), such as the cyclic nucleotides (cAMP and cGMP), Ca , and inositol
1,4,5-trisphosphate (IP3), that apart from initiating the respective phosphorylation
cascade, also modulate other protein functions and enzyme activity. Thus the second
messenger system provides both an amplification function, where many readily
diffusible molecules of the second messenger can be generated in response to a
single molecule of the extracellular stimulus, and an additional regulatory and
1
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integrative junction where both the synthesis and degradation of the signal
transducing molecule can be modulated. It has been increasingly clear that extensive
crosstalk can occur between many signalling pathways to integrate intracellular
signalling and responses to the environmental stimuli [3-5], Therefore,
understanding the signal transduction mechanism underlying a physiological process
and its interaction with other signalling pathways is fundamental to our
understanding of its various modes including those that lead to malfunction/diseases.
2
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1.1.1 The cAMP pathway: in the era of multiple isozymes/splice
variants and signal integration
Adenosine 3',5'-cyclic monophosphate (cAMP) was first isolated and characterised
more than four decades ago [6, 7], closely followed by reports of the enzymes
responsible for its formation [8] and degradation [9], the adenylyl cyclase (AC) and
cyclic nucleotide phosphodiesterase (PDE) respectively. Importantly, the existence
of these enzymes capable of regulating the intracellular level of cAMP serves to
fulfil the criteria for cAMP to function as an intracellular second messenger. Many
hormones and neurotransmitters have since been shown to activate cAMP synthesis
by AC via transmembrane signalling through agonist-specific G-protein coupled
receptors (GPCRs). The level of intracellular cAMP is then a balance of the AC and
PDE activities, which will determine the extent of activation of its intracellular
effector, the cAMP-dependent protein kinase (PKA). PKA can then elicit both short-
term (within min) and long-term (from h to days) regulation via phosphorylation of
functional proteins that mediate the agonist actions [10]. The discovery of new
signalling components, new interactions with other signalling pathways, and novel
regulatory mechanisms (such as spatial and temporal factors) have revealed further
the complexity and versatility of the cAMP signal transduction. In addition to PKA,
cAMP is now known to directly regulate other intracellular effectors including the
cyclic nucleotide-gated ion channels (reviewed in [11, 12]) and a newly described
family of cAMP-binding proteins with guanine nucleotide exchange factor activity
(cAMP-GEFs) that directly activate the Ras superfamily guanine nucleotide binding
protein Rapl [13, 14], PKA is also found to be negatively regulated directly by a
family of endogenous inhibitors, PKIa [15], PKI|3 [16], and PKIy [17], that exhibit
tissue- and developmental-specific expression [18] and are themselves regulated by
3
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hormone stimulation [19], synaptic stimulation [20], and cell cycle [21]. The cross-
activation of cGMP-dependent protein kinase (PKG) by cAMP and PKA by cGMP
have been documented [22, 23]. PKA-phosphorylated targets can be rapidly and
selectively dephosphorylated by a growing superfamily of protein phosphatases [24],
providing means for reversing the PKA action and for additional specificity in the
regulation by this covalent modification [1], Furthermore, there is an increasing
appreciation of the importance of architectural organisation of signalling components
in signal transduction, and the idea of the cell as a membrane-enclosed solution of
proteins to which stochastic enzymatic theories apply is now replaced by a picture of
a highly organised space in which most enzymes and proteins are linked in
complexes by scaffolding and anchoring proteins through specific interacting
domains [25-28]. The resulting architectural network of signalling components is
thought to facilitate and to enable both versatility and specificity of intracellular
signal transduction. Extensive molecular cloning has revealed further complexity
within each component of the cAMP pathway, many of which, such as the protein
kinases [2], protein phosphatases [24], ACs [29, 30], and PDEs [31, 32], are now
known to each consists of a superfamily of isozymes encoded by distinct genes.
Multiple isozymes of these components are found to co-exist in a single cell type.
This diversity provides the mean for intricate and co-ordinated regulation of
intercellular and intracellular events as these isozymes can be regulated differentially
and have different kinetic properties. The challenge now is to elucidate and




1.1.2 Implications for studying the molecular mechanism of
physiological processes
The multiplicity of signalling components, with both unique and overlapping
functions has made it necessary to identify the exact components/isozymes/splice
variants involved in a physiological process in order to understand their integrative
role. The importance of crosstalk between signalling pathways and architectural
organisation of signalling components in cell functions has cautioned interpretation
of our experimental findings. Results obtained from in vitro systems or from studies
looking at only a subset of the components known to be involved in a physiological
process may not reflect the physiological relevance or significance. The dynamics of
molecular events and their co-regulation by multiple factors, which will determine
their functionality, may not be the same under different environments. Furthermore,
the immense capacity of endogenous compensatory mechanisms in the cells can
mask important functional roles of the protein under investigation. For example, it is
commonly observed that conditions leading to an increase in cAMP synthesis by AC,
such as constitutively active Gsa mutation [33, 34], are accompanied by an increased
in PDE activity, such that the intracellular cAMP levels were only slightly elevated.
Studies from transgenic mice have also shown increased expression of other proteins
that compensate for the function of the gene that has been deleted [35-37].
Nevertheless, determination of the different isozymes of signalling components
expressed in a system and their regulatory potential is crucial for hypothesising and
finding out their exact physiological functions.
5
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1.2 Cyclic Nucleotide Phosphodiesterases
The only route of enzymatic inactivation of cAMP and cGMP known to date is
through the cyclic nucleotide phosphodiesterases (PDEs). Concepts on the role of
cyclic nucleotide hydrolysis in signal transduction have evolved from viewing PDEs
as passive terminators of the cyclic nucleotide signalling to the present level of
understanding where PDEs are regarded as targets of complex regulation by various
intracellular signalling pathways [31, 32, 38, 39]. Up to 10 different gene families of
PDEs (coding for more than 30 different isozymes) have now been identified in
mammals based on their distinct kinetic and substrate characteristics, inhibitor
profiles, allosteric activators and inhibitors, and amino acid sequence (Table 1) [31,
32, 38, 40-45], A general nomenclature for naming PDEs has been adopted [46]: 1.
The first 2 letters represent the species, for example, HS for human, MM for mouse,
and RN for rat. 2. The next 3 letters plus an Arabic numeral represent the PDE gene
family. 3. The next letter represents individual gene product within the family. 4.
The final Arabic numeral represents the splice variant. Multiple isozymes and splice
•*> |
variants within a family are known to exist, particularly in the PDE1 (Ca /CaM-
stimulated) and PDE4 (cAMP-specific, rolipram-inhibitable) families. These
isozymes are expressed in distinct tissue- and cell-specific fashions, with discrete
subcellular localisations, and exhibit distinct, but functionally concerted modes of
regulation at the levels of mRNA transcription and post-translational modification
[31, 38, 39], Species-specific expression of the PDE isozymes in some tissues has
also been reported [47-49]. These highlight the remarkable versatility of this
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1.2.1 Structure and Function of PDEs
Peptide mapping and mutagenesis studies have revealed a core catalytic domain of
about 250 amino acids near the carboxyl-terminal half that is conserved among all
PDEs [50-53]. This region is much more similar within an individual PDE family
(>80% identity) than between different PDE families (25-40% identity) [53], and is
thought to contain common structural elements important for hydrolysis of the cyclic
nucleotides, as well as family-specific determinants responsible for differences in
substrate affinities and inhibitor sensitivities among the different PDE gene families
[54].
The widely divergent N-terminal domain of PDEs contains determinants that confer
regulatory properties specific to the different gene families and splice variants [31,
32, 38]. For example, CaM-binding in PDE1; non-catalytic cGMP-binding in PDE2,
5 and 6; subcellular-targeting and protein-protein interaction in PDE4; hydrophobic
membrane-association in PDE3 and 4; and phosphorylation in PDE1, 3, 4 and 5 [31,
32, 38, 55]. In general, part of the amino-terminal domain of several isozymes is
thought to cause intramolecular inhibition of the catalytic activity, and the activation
of these isozymes appeared to involve the removal of this self-inhibition albeit by
different mechanisms. For example, CaM binding in PDE1 [56], PKA
phosphorylation in PDE4D3 [57], activation of the long forms of PDE4 isozymes
(PDE4A5,PDE4B1, and PDE4D3) by phosphatidic acid [58, 59], and proteolytic
cleavage separating the amino-terminal fragment from the catalytic domain in PDE1
[60, 61] and PDE4 [50],
8
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1.2.2 The PDE1 Family: the second checkpoint of cAMP pathway
by Ca2+/CaM
94-
Since the first report in the rat brain [62], the Ca /CaM-stimulated PDE1 activity
has been detected and characterised in other mammalian tissues (for a recent review,
refer to [63]). To date, three different genes (PDE1A, PDE1B, and PDE1C) have
been identified in the PDE1 family [63-67], Two splice variants from the bovine
PDE1A gene, PDE1A1 and PDE1A2 have been isolated, which differ only in a short
amino-terminal segment (PDE1A1 = 18 residues; PDE1A2 = 34) that constitutes part
of a putative CaM-binding site [56]. This difference is likely to account for the
9+
observation that PDE1A1 has about 10-fold higher affinity for Ca /CaM compared
to PDE1A2 [56, 67-69]. So far only one mRNA product has been isolated from the
PDE1B gene coding for PDE1B1, although RNase protection assays have also
detected structurally related PDE1B variants in brain, kidney, and adrenal medulla
[66]. Both PDE1A and PDE1B isozymes hydrolyse preferentially cGMP to cAMP
at micromolar substrate concentrations, but their maximum rate of cAMP hydrolysis
is higher than or equal to that of cGMP [31]. As the tissue level of cAMP is
generally an order of magnitude or more higher than cGMP, it has been postulated
that these enzymes serve to hydrolyse both cyclic nucleotides in vivo [70-72],
Although PDE1 activity showing high affinity for cAMP has been observed for a
long time by many investigators [73-82], it was only recently characterised as a new
PDE1 gene and named PDE1C [83]. To date, the PDE1C gene has been shown to
generate up to five different splice variants (PDE1C1-5) that are expressed in a
tissue-specific manner and showed differences in inhibition by some PDE1 inhibitors
and sensitivity towards stimulation by Ca2+/CaM [49, 84], The fact that PDE1C
isozymes hydrolyse both cAMP and cGMP with high affinity (about 1 pM) and
9
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similar capacity, together with its activation by cellular levels of Ca2+ and
calmodulin, strongly implicate their important role in regulating intracellular cyclic
• 9 i
nucleotide levels with respect to the Ca /CaM status of the cell.
PDEls are unique among other PDEs in that their activities can be dramatically
stimulated by Ca2+/CaM, and thus serve as the second checkpoint (after Ca2+/CaM-
regulated ACs) of the cAMP pathway by Ca2+/CaM. Several lines of evidence have
supported the regulation of intracellular cAMP level by PDE1 activity in response to
94- •
changes in intracellular Ca [85, 86]. The functional significance of such a
regulatory role has been implicated in the central nervous system, the olfactory
neurons, the cardiovascular system and the testis (reviewed in [63]). In addition,
PDEls have also been found to be involved in many cell functions such as insulin
action [87], leukemic cell survival [88], cell proliferation [33, 48, 89, 90], and cell
development [75, 91].
In addition to regulation by Ca2+/CaM, both PDE1A and PDE1B have been shown to
be phosphorylated in vitro by PKA [69, 92] and CaMK II [93] respectively. In both
cases, phosphorylation was found to decrease the sensitivity of the enzymes towards
Ca2+/CaM stimulation. This effect is highly significant as the dynamic range of
Ca2+/CaM-stimulated PDE1 activity is very wide (10-fold or more). However, the in
vivo regulation of these PDEls by phosphorylation has not been demonstrated yet.
In the in vitro system, the main PKA phosphorylated residues in BTPDE1A2 have
been mapped to Serl20 and Serl38, of which only PKA phosphorylation of Serl20
was found to reduce sensitivity toward CaM stimulation [92]. Interestingly,
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sequence analysis has indicated that both PKA phosphorylation sites in PDE1A were
also present in PDE1C isozymes [84], but there is no report yet regarding this
potential regulation in vitro or in vivo. More recently, limited proteolysis through a
Ca2+-dependent cysteine protease, m-calpain, whose cleavage site is found in all
PDE1 isozymes described so far, has been suggested as an additional mechanism for
activating PDEls [61]. Several studies have also demonstrated 'long-term' regulation
of PDEls through altered gene expression [33, 48, 89, 90, 94]. For example, the
Chinese hamster ovary (CHO) cells, which normally do not express detectable PDE1
activity, were found to transiently express PDE1B isozyme with the characteristics of
an immediate early gene upon receptor-mediated elevation of DAG levels [89, 94],
Thus, PDE1 isozymes can be regulated by multiple mechanisms, supporting that they
2~F
probably serve an important role in integrating cAMP and Ca signalling.
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1.2.3 The PDE4 Family: diverse and versatile regulation of cAMP
hydrolysis
Of all the PDE families, that of PDE4 has received the most attention and perhaps
consequently is the best studied PDE family so far. There are various reasons why
this is so: 1. PDE4s are the mammalian homologues of the Drosophila dunce gene
that was the first and best characterised mutant shown to be critical for learning and
memory [95-97], Remarkably, a rat cDNA homologue of dunce, RD1 [96] (known
now as PDE4A1), was able to rescue the phenotypes (defects in learning and
memory, and female sterility) caused by mutations in Drosophila dunce gene [98].
2. PDE4s are selectively inhibited by the antidepressant rolipram {4-[3-
(cyclopentoxyl)-4-methoxyphenyl]-2-pyrrolidone} and structurally related
compounds, and thus implicated in the control of mood [97]. 3. PDE4s are involved
in the regulation of a wide range of processes including desensitization to hormonal
stimulation [99], cell survival [100], tumour growth [101], reproduction [102, 103]
and activation of the immune response [104],
Evidence for the presence of at least four different PDE4 genes was first
demonstrated in rat [96, 105, 106], and was subsequently shown in mouse [107] and
human [108]. The four genes code for the PDE4A, PDE4B, PDE4C and PDE4D
subfamily of isozymes. Multiple alternative splice variants from each of these genes
(with the exception of PDE4C) have been cloned and characterised (reviewed in
[55]). For example, up to 5 distinct splice variants produced from the PDE4D gene
has been shown to exist in man [109] and rat [110] at the level of both mRNA and
protein expression. The 2 short (PDE4D1, 2) and 3 long (PDE4D3, 4, 5) forms of
PDE4D are generated by alternate N-terminal splicing. Similarly, at least 3 splice
12
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variants of PDE4A and PDE4B are known to exist [55]. Importantly, these splice
variants have been shown to be differentially regulated by activation of the cAMP
pathway in many cell types. In human promonocytic cell line, U937, short-term (2-
20 min) treatment with prostaglandin E2 produced a rapid activation of PDE4D3
activity by PKA phosphorylation [111], while prolonged (2-4 hr) exposure to
prostaglandin E2, salbutamol, and 8-bromo-cAMP resulted in an increased
expression of PDE4A (125 kDa) and PDE4B (70 kDa) isozymes [112, 113]. In rat
FRTL-5 thyroid cell, thyroid stimulating hormone induced both a rapid (within min)
activation/phosphorylation of PDE4D3 activity as well as an increased in gene
expression of PDE4D1/PDE4D2 splice variants after prolonged stimulation [110,
114], Many studies have suggested that the unique N-terminal regions of the various
PDE4 splice variants may govern protein-protein interaction, intracellular targeting,
as well as regulation by phosphorylation (reviewed in [55]).
13
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1.2.4 Role of PDEs in cAMP signal transduction
A common feature of the hormone-dependent cAMP regulation is the transient
nature of the increase in intracellular cAMP, that after an initial increase, the cAMP
concentration returns toward basal levels. This phenomenon is thought to be
associated with the refractoriness of the target cell that follows hormone stimulation,
a crucial factor that determines cell responsiveness to hormones. There are multiple
mechanisms involved in cell desensitization, including changes in the components of
the signal transduction machinery at the plasma membrane as well as the expression
of intracellular mechanisms terminating or limiting the effect of hormonal
stimulation [115, 116]. These homeostatic mechanisms enable the cells to generate
appropriate response and to adapt to acute and chronic hormone stimulation.
The significance of PDE activity in limiting basal and agonist-stimulated
intracellular cAMP levels was evident for a long time, mainly through observations
of the dramatic increase and prolonged agonist-induced cAMP accumulation in the
presence of PDE inhibitors that was often translated to an increase in hormone
secretion. Furthermore, an induction of PDE activity upon stimulation by cAMP-
generating hormone/agonist has been well documented in many systems and appears
to be a ubiquitous phenomenon, where an increase in cAMP breakdown by PDEs
contributes to the termination of the agonist signal and to the development of
desensitization [110, 112, 117-129]. In both Sertoli and FRTL-5 thyroid cells,
prolonged stimulation with FSH and TSH respectively (or with PDE-resistant cAMP
analogues), leads to an induction of PDE4D2 mRNA and protein expression. In
addition, there is a rapid activation of PDE4D3 activity by PKA phosphorylation in
14
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FRTL-5 cell. These findings demonstrate that intracellular feedback loops linking
cAMP concentration and PDEs are operative in the cell and involve both rapid
(short-term) post-translational modifications as well as long-term changes in PDE
gene expression. A pathological model where an increase in cAMP-hydrolysing
activity was found to cause hormone insensitively is present in a strain of
nephrogenic (vasopressin-resistent) diabetes insipidus (NDI) mice [130, 131].
Cultured cells from the inner medullary duct from the kidneys of these mice do not
respond to vasopressin in spite of an apparently normal complement of receptors and
the normal ability of vasopressin to stimulate adenylyl cyclase in a cell-free system
[132, 133], Application of a PDE4-specific inhibitor, rolipram, either in vitro or in
vivo restored the responsiveness to vasopressin-stimulated cAMP accumulation and
water permeability of the renal collecting system in these mice [131, 134]. These
findings indicate that PDE activity has a major impact on cell responsiveness to
hormones and suggest the possibility that other syndromes of cell insensitivity or
hormone resistance might be due to an alteration of PDE activity.
In addition to mediating feedback function, cAMP-hydrolysing PDEs which are
9+
regulated by other second messengers, such as Ca /CaM (activating PDE1) and
cGMP (inhibiting PDE2 and activating PDE3), may function as targets for crosstalk
between stimulatory and inhibitory signals regulating cellular activity. Agonist-
induced intracellular Ca2+ elevation has been shown to increase cAMP degradation
via the activation of PDE 1 activity in dog thyroid slices [135], rat cardiomyocytes
[136] and cultured human astrocytoma cells [118]. In bovine glomerulosa cells of
the adrenal cortex, atrial natriuretic peptide (ANP), which increases cGMP level, was
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found to reduce ACTH-stimulated cAMP accumulation and aldosterone secretion via
the activation of PDE2 [137], Similar effects of ANP on agonist-stimulated cAMP
levels in fibroblasts [138] and in PC-12 cells [139] have also been reported. On the
other hand, in tissues where cAMP and cGMP have similar physiological effects,
PDE3 serves as a target for cGMP to act synergistically with cAMP signalling [140,
141]. Thus, in addition to their general function as negative modulators of cyclic
nucleotide signalling, PDEs serve as targets for integrating other intracellular signals.
Recent imaging studies using a cAMP fluorescent probe, FICRhR [142], have
9+
demonstrated that as with Ca signals [143, 144], there is also spatiotemporal
dimension in cAMP signals [145, 146]. The FICRhR consists of the PKA
holoenzyme complex, R2C2, in which the catalytic (C) and regulatory (R) subunits
are labelled with fluorescein and rhodamine respectively. The dissociation of the C
subunits upon cAMP binding to the R subunits disrupts the fluorescence resonance
energy transfer (FRET) present in the holoenzyme complex, and results in a change
in the fluorescence emission spectrum that can be visualised in living cells [142],
Using this approach, different neuromodulators were found to generate unique
pattern of cAMP transients in different neurons of the lobster stomatogastric
ganglion [146], Furthermore, in an elegant study using whole cell patch-clamp
technique on cardiac myocytes, cAMP was shown to diffuse minimally from the site
of synthesis under normal conditions of agonist stimulation resulting in local
activation of Ca2+ channels, while inhibition of PDEs causes a rapid diffusion of
cAMP throughout the cell leading to increased activation of distant Ca2+ channels
[147]. This provides supporting evidence to the postulation that PDEs may play an
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important role in limiting cAMP diffusion [148], which together with other
mechanisms, contribute to the specificity of cAMP signalling. This function is likely
to be enhanced by the localisation of PDE isozymes in different subcellular sites. To
this end, even though it has been known for a long time that a portion of the cellular
PDE activity is recovered in the particulate fraction [149], the underlying molecular
basis is only recently under intense investigation. This is probably due to both the
identification of multiple PDE isozymes/splice variants with distinct sequences
outside the conserved catalytic domain that contain targeting/interacting motifs and
the emerging theme of targeting in signal transduction. While some PDE isozymes
(PDE3B, PDE4A1, PDE7A2) possess a hydrophobic membrane targeting sequence
[150-153], examples of specific interaction of PDE4 isozymes/splice variants with
adaptor/scaffold proteins are emerging. For example, the amino-terminal proline-
arginine motifs (PxxPx-R) of PDE4A5 enable interaction with selective SH3
domains, particularly those from Src family tyrosyl kinases, Lyn and Fyn [154, 155],
More recently, an unique amino-terminal region of PDE4D5 was shown to confer
high affinity interaction with RACK1 in vitro and in intact cells [156],
Immunofluorescence studies have also shown differential subcellular localization of
PDE4D splice variants in the cell that correlated well with observations by
differential centrifugation [114]. Collectively, the accumulating evidence
demonstrating that specific PDE isozymes/splice variants are differentially regulated
and targeted to different subcellular locations strongly support the hypothesis that




1.2.5 Methods for determining the PDE profile
Several approaches have been used to characterise the PDE activities in a cell system
(reviewed in [157]). There are family-specific PDE inhibitors and modulators (see
Table 1) that can be used to differentiate PDE activities contributed by different
isozymes [46], Substrate saturation studies with cAMP and cGMP can also
distinguish between PDE families (in the case of PDE1 family, may even
differentiate PDE1C from PDE1A and PDE IB based on its low Km for cAMP).
Anion-exchange chromatography has proved to be an effective mean of separating
some PDE families from each other and in some cases from their modulators present
in cell extracts (for example, PDE1 and CaM). The fractions containing partially
purified isozymes can then be used for more detailed kinetic analysis or for further
purification. The reverse transcription-polymerase chain reaction (RT-PCR) has
proven to be a powerful method that allows identification to the level of splice
variants. More importantly, the development of antibodies against different PDE
isozymes in many laboratories have provided definitive evidence to the identification
and confirmation of expression at the protein level. These antibodies have also been
used to isolate specific isozymes by immunoprecipitation, which when coupled with
other methods (such as PDE activity measurement and SDS-PAGE) provide a very
powerful mean in attributing regulation to specific isozymes. Using these methods
one could have an idea of the involvement of specific PDE isozymes in the system of
interest, and further detailed analysis can then be carried out if necessary.
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1.3 Regulation of ACTH secretion in anterior pituitary
corticotrophs
The secretion of adrenocorticotrophic hormone (ACTH) by the anterior pituitary
corticotrophs is a crucial process in the activation of hypothalamic-pituitary-
adrenocortical (HPA) axis in response to stress and to maintain homeostasis. Thus it
is not surprising that ACTH secretion is tightly regulated by multiple factors.
Although the principal physiological ACTH secretagogue is the hypothalamic
neuropeptide, corticotropin-releasing factor (CRF), it is clear that interactions with
other regulators including arginine vasopressin (AVP), angiotensin II (All) and
catecholamines, are necessary for the sustained increases of ACTH secretion in
conditions such as stress [158-161], The main inhibitory factor is the end product of
HPA axis activation, the adrenalcortical glucocorticoid, which exerts a powerful
negative feedback inhibition at several levels along the HPA axis including the
anterior pituitary corticotrophs [162].
It is well established that CRF signals primarily through the cAMP pathway to
stimulate ACTH secretion [162]. The role of Ca2+ in ACTH secretion, and other
hormone secretion for that matter, is more complicated, as it serves both facilitatory
and inhibitory actions [162, 163]. This is not surprising considering in addition to
9+
the unique spatiotemporal dynamics of intracellular Ca , there is a diverse range of
functional proteins that are regulated by Ca2+ alone or in combination with CaM
[164], Indeed, CRF stimulation is known to trigger oscillations of intracellular Ca2+
concentration that are essential for ACTH release [165, 166]. These oscillations may
be the result of intracellular Ca2+ negative feedback loops [162]. Notably, the early




act through this Ca feedback loop and requires the induction of new proteins [166,
167], Importantly, in the presence of AVP, which potentiates CRF-induced cAMP
accumulation and ACTH secretion, the resulting ACTH secretion is resistant to
glucocorticoid inhibition [168-170]. As AVP action is mediated primarily by a
different signalling pathway, acting through the inositol 1,4,5-triphosphate
(IP3)/protein kinase C (PKC) pathway [171, 172] and may utilise a different ACTH
[169, 173] and Ca2+ [174, 175] pools, the escape of ACTH secretion from
glucocorticoid inhibition could be due to a switch in the components regulating
cAMP synthesis and degradation such that they are not longer susceptible to the
Ca2+-feedback [162], Importantly, when corticotrophs were stimulated with CRF or
cAMP analogue before and during subsequent glucocorticoid treatment, the early
glucocorticoid feedback can be inactivated [176]. Thus it appears that glucocorticoid
feedback inhibition is operative to maintain homeostasis, but is blocked under certain
stressful situations where the signalling of ACTH secretagogues overwhelmed.
Therefore in the physiological context, the interaction of CRF with other ACTH
secretagogues and glucocorticoid signalling in corticotrophs is likely to be dynamic




1.4 The AtT20 cell as a model for studying anterior pituitary
corticotroph function
The low proportion of corticotrophs in the adenohypophysis and the ubiquitous
expression of many proteins make the biochemical characterisation of functional
proteins regulating ACTH secretion in corticotropes extremely difficult. The mouse
pituitary tumour cell line AtT20 was established from pituitary tumour found to
retain the major characteristics of corticotrophs [177] and thus provides a nominally
homogeneous population of cells for the characterisation and study of factors
involved in the regulation ofACTH secretion. In these cells, the early glucocorticoid
inhibition has similar properties as in normal corticotrophs [178, 179], The
hallmarks of early glucocorticoid: onset within 2 h, mediation by type-2
glucocorticoid receptor, requirement for mRNA and protein synthesis, could be
demonstrated in AtT20 D16:D16 cells [179], To this end, AtT20 cells have been
used extensively to study the molecular mechanism underlying the regulation of
ACTH secretion [180-193],
Previous studies in this laboratory using AtT20 cells have shown that, as in normal
rat corticotrophs, there is a pronounced feedback inhibitory effect of intracellular
Ca2+ on agonist-induced cAMP accumulation (summarised in [162]). Importantly,
this inhibitory Ca2+ effect is found to be mediated through calcineurin, a Ca2+/CaM-
2"b
stimulated protein phosphatase (PP2B) [181]. In addition, two targets of Ca
feedback in AtT20 cells have been identified, a novel isotype of AC that is inhibited
by Ca2+, AC9 [181], and the Ca2+-activated BK-type K+ channels [180]. In addition,
glucocorticoid-induced calmodulin [182] may also directly interact with these and
other cellular targets (such as PDE1) to mediate the feedback inhibition of agonist-
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induced ACTH secretion. These findings indicated that the glucocorticoid feedback
inhibition of ACTH secretion is multifactorial and involved the co-ordinated
regulation ofmultiple intracellular signalling components.
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1.5 Role of PDEs in the regulation of ACTH secretion
Corticotroph cells exhibit spontaneous as well as agonist-induced action potentials
[194] and intracellular Ca2+ transients [165, 166, 195]. In this system cAMP-
dependent phosphorylation has a prominent role in the control of the membrane
94-
potential through regulation of L-type Ca channels [196, 197] and BK-type
potassium channels [180]. Alterations in the rate of cAMP hydrolysis are therefore
bound to be critically important in regulating various aspects of intracellular Ca2+
transients such as amplitude, duration, rate of increment and decrement, all of which
9"b •
may contribute to the decoding of the intracellular Ca and cAMP signals by various
intracellular target proteins [198],
Early studies have indicated the presence of multiple PDE activities in the rat and
bovine anterior pituitary [199, 200]. Ca2+/CaM-stimulated PDE activity and both
low (about 1 pM) and high (10-20 pM) Km cAMP-PDE activities were observed
[199, 200]. These kinetic characteristics, together with their chromatographic
profiles, clearly indicated the presence of PDE1 and plausibly PDE4 activities.
Several studies have shown that PDE activity in anterior pituitary cells is regulated
by hormone stimulation. AVP treatment was found to inhibit a high-Km
phosphodiesterase activity in rat anterior pituitary cells [168]. Somatostatin, which
inhibits ACTH secretion, has been shown to stimulate PDE activity in rat anterior
pituitary [201]. Studies using PDE inhibitors have shown that CRF-induced ACTH
secretion was equally enhanced by rolipram and IBMX, whereas IBMX was more
effective than rolipram in enhancing AVP-induced ACTH secretion [202]. This
suggests that PDE4 contributes the main cAMP-hydrolysing activity during CRF
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stimulation, while other PDEs in addition to PDE4 are involved in AVP stimulation.
More recently, in vivo and in vitro pharmacological studies have shown the
stimulation of HPA axis by PDE4 inhibitors [203], implicating a critical role for
PDE4 in the control of corticotroph cell function. Previous studies in this laboratory
have observed that inhibition of protein phosphatase 1/2A (PP1/2A) in AtT20 cells
leads to a dramatic decrease of CRF-induced cAMP accumulation which appears to
involve a reduction of Gs activation of AC and is also partly mediated by an
activation of PDE activity [204], Importantly, the inhibitory effects of
T_|_ . . . ,
Ca /calcineurin on cAMP accumulation could not be observed in the presence of
calyculin A, suggesting that PP1/2A function is permissive for the Ca2+ feedback
regulation [181, 204], These results undoubtedly indicated an important role of
PDEs in the regulation of ACTH secretion at the level of anterior pituitary
corticotrophs.
The PDE profile of adenohypophysis and AtT20 cells have not been examined in
detail with respect to the expression of specific isozymes. Furthermore, while the
inhibitory action of Ca2+ on cAMP synthesis in these systems is well documented
(summarised in [162]), it has not been explored with respect to cAMP degradation by
PDEs. With the current knowledge of the PDE superfamily, it is important to
identity and to study the regulation of specific PDE isozymes that are involved in
these processes to further our understanding of the molecular mechanism governing
the regulation ofACTH secretion.
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1.6 Aims and objectives of this thesis
This thesis has two fundamental objectives that were designed to compliment
ongoing functional studies of the regulation of ACTH secretion in adenohypophysis
in this laboratory:
1. To identify the cAMP-hydrolysing PDEs in anterior pituitary cells, primarily that
of the experimental model, AtT20 cells. This would be accomplished by multi-
faceted analysis using biochemical (kinetic studies, chromatographic separation),
pharmacological (subfamily-selective PDE inhibitors), molecular (RT-PCR), and
immunological (immunoprecipitation and immunoblot) methods.
2. To examine the potential regulation of PDEs in AtT20 cells by the cAMP-
dependent pathway. Intact cells studies looking at the effects of CRT and a cell-
permeable cAMP analogue on PDE activity will be carried out. In addition, in
vitro treatment of cell extracts with PKA catalytic subunit will be performed.
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2 MATERIALS AND METHODS
2.1 Biochemicals
All reagents were of the highest grade available and obtained from Sigma-Aldrich
(Poole, Dorset, UK) unless otherwise stated. The following compounds were
generously provided by the manufacturers: rolipram (Schering A.G., Berlin, F.R.G.),
Zaprinast (Rhone Poulenc Rhorer Ltd, Dagenham, UK), and vinpocetine (Gedeon
Richter Ltd, Budapest, Hungary). Dulbecco's modified Eagle's medium (DMEM),
Hank's balanced salt solution (HBSS) and Geneticin® (G418 sulphate) were
purchased from GIBCO BRL, Paisley, Strathclyde, UK. Foetal calf serum (FCS)
was from Seralab, Crawley Down, Sussex, UK. [2,8,5- HJadenosine, [2- H]5'-
AMP, and [2,8-3H]3',5'-cAMP were from Dupont, Stevenage, UK or Amersham,
Little Chalfont, UK. GF/C filter was from Whatman, Maidstone, Kent. SDS-
electrophoresis calibration kit was from Pharmacia, St Alban, Herts, UK. Immobilon
membrane was from Millipore. Acrylamide/bis-acrylamide was from Bio-Rad,
Herfordshire, UK. HRP-anti-rabbit IgG was from SAPU, Lanarkshire, Scotland,
UK. CRF and protein kinase A inhibitor peptide (TTYADFIASGRTGRRNAIHD)
were from Bachem, UK. CPT-cAMP was from BIOLOG, Bremen, Germany.
Calyculin A was from Alexis, Nottingham, UK. H-89 {A-[2~[[3-(4-bromophenyl)-2-
propenyl]amino]ethyl]-5-isoquinoline sulfonamide} was from Calbiochem,
Nottingham, UK or Biolog, Bremen, Germany. PKA catalytic subunit (purified from
bovine heart) was from Promega, Southampton, UK. Recombinant PKA catalytic
subunit was a generous gift from Dr. R. Clegg, Hannah Institute, Ayr, UK
(recombinantly expressed murine Ca, purified from E. coli [205]).
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2.2 Preparation and storage of stock solutions
PDE inhibitors were dissolved in dimethylsulphoxide (DMSO) to 0.1-0.5 M,
aliquoted and stored at -20 C. 0.1 mM CRF was prepared in 1 mM ascorbic acid
and 10 mM HC1, aliquoted and stored at -70 C. CPT-cAMP was dissolved in
distilled water to a 50 mM stock solution, aliquoted and stored at -40 C. Calyculin
A was dissolved in ethanol to a 100 pM stock solution and stored at -40 C. H-89
was dissolved in DMSO to a 10 mM stock solution and stored at 4 C. 10 pM
calmodulin was prepared in 0.1% BSA, aliquoted and stored at -40 C.
Phenylmethylsulphonylfluoride (PMSF) was prepared fresh in ethanol to 100 mM.
Dithiothreitol was dissolved in distilled water to a 100 mM solution, aliquoted and
stored at -20 C. 17.5 mM Ba(OH)2 was prepared fresh for each PDE assay.
2.3 Cell lines
AtT20 D16:16 mouse anterior pituitary tumour cells were kindly provided by Dr S.
L. Sabol, National Institute of Health, Bethesda, MD, USA [177]. Human
embryonic kidney (HEK293) cells were kindly provided by Dr. L. Anderson,
Medical Research Council Reproductive Biology Unit, Edinburgh, Scotland, UK.
2.4 Cell culture
AtT20 cells were maintained as monolayer culture in DMEM with 2.5g/L glucose,
supplemented with 10% FCS and in an atmosphere of 5% CC>2/95% air at 37 C
[179]. AtT20 cells were passaged every 7 days. All experiments were performed on
cells between passage 10 to 30. HEK293 cells were maintained as AtT20 cells
except that they were passaged every 4 days. HEK293 cells stably transfected with
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pCI-HSPDE4D3-VSV plasmid (HEK293-4D3-VSV) were maintained as HEK293
cells except that 0.6 mg/ml Geneticin® was included in the growth medium to
maintain selection pressure.
2.5 Cell treatment
Cells were detached from the tissue culture flasks with HBSS supplemented with
0.1% EDTA, pelleted at 200g for 5 min, resuspended at approximately 106 cells/ml
(counted with a haemocytometer), aliquoted (0.5-2 ml per treatment) and
preincubated in the incubation buffer (HBSS containing 25 mM HEPES, pH 7.3-7.4,
2 mM CaCh, 1 mM MgSC>4 and 0.25% (w/v) BSA) for 30 min at 37 C with gentle
shaking or end-on-end turning. Vehicles or drugs were then applied and incubated at
37 C for the indicated times. Treatments were terminated by transferring the cells
to an ice-bath for 5 min. The experiments with CRF were performed with AtT20
cells plated in 24-well tissue culture trays [179].
2.6 Preparation of cell extracts
After termination of the treatment, cells were pelleted at 200g for 5 min at 4 C a n d
washed twice with ice-cold incubation buffer without BSA. The cell pellets were
then resuspended (2-10xl06 cells/ml) in a homogenisation buffer (HB) containing 20
mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.2 mM EGTA, 50 mM NaF, 10 mM sodium
pyrophosphate, 50 mM benzamidine, 0.5 pg/ml leupeptin, 0.7 pg/ml pepstatin, 4
pg/ml aprotinin, 10 pg/ml soybean trypsin inhibitor, 2 mM PMSF and 1 mM DTT,
and lysed by freeze-thawing (liquid N2 and 30 C until just thawed and then kept on
ice). The homogenate was centrifuged at 200g for 10 min, 4 C, and the resultant
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supernatant was spun at 30,000g for 20 min, 4 C, to obtain the cytosolic fraction
(i.e. supernatant of 30000g). Protein content was quantitated using Coomassie
Protein Assay Reagent (Pierce, Chester, UK) with BSA as standard [206],
2.7 Preparation of extracts from anterior pituitary glands and rat
brain
Male Wistar rats (150-200g body weight; Harlan-Olac, Bicester, UK) were housed in
individual cages for 24-48 h under controlled lighting and air conditioning, with free
access to tap water and food pellets. Animals were killed by decapitation between
8:30 and 9:00 AM, taking precautions to avoid stressful stimulation. Adult balb/c
mice were similarly treated. The anterior pituitary glands were excised and
immediately processed for RNA extraction (detailed below) or homogenised with a
Teflon-glass homogenizer (3 x 20 s) in 10 volumes of the same homogenization
buffer used for AtT20 cells. The rat brains were removed and homogenised as




2.8.1 ZnS04-Ba(0H)2 precipitation method
PDE activity was measured by minor modifications of a radiometric assay [207]
based on the precipitation of the cAMP hydrolysis product, 5'-AMP, with ZnSC>4-
Ba(OH)2 treatment [208], The PDE assay buffer contained 100 mM Tris-HCl, pH
7.5, 5 mM MgSC>4, 10-20 pi of cell extract (1-10 pg protein), and other additions for
defining different PDE activities (detailed below), in a total volume of 150 pi. After
preincubation at 30 C for 5 min, the reaction was initiated by the addition of 50 pi
substrate mixture to give a final concentration of 1 pM cAMP and 0.2 pCi/ml [2,8-
3H]cAMP. The PDE assay was then incubated at 30°C for 5-30 min. The reaction
was terminated by the addition of 100 pi of 21.5 mM ZnSC>4 followed by 100 pi of
17.5 mM Ba(OH)2 to precipitate the 5'-AMP formed. The suspension was filtered
over Whatman GF/C filters on a vacuum manifold, and washed twice with 3 ml of 1
mM NaOH/100 mM NaCl. Radioactivity retained on the filters was measured by
liquid scintillation counting with 10 ml of Emulsifier-SAFE™ scintillation cocktail
(Packard Bioscience, Pangbourne, Berkshire, UK). The % recovery (68 ± 2%,
mean±S.E.M., n=18) of the counts (precipitates) was monitored with El-AMP in
place of 3H-cAMP. Blanks were either with homogenisation buffer in place of cell
extracts or with heat-inactivated (90 C, 5 min) cell extracts which gave similar
results and were less than 2% of the total H-cAMP added. PDE assay of each
sample was performed in duplicate or triplicate. The coefficient of variation between
the PDE assay triplicates was usually below 3%. To ensure cAMP hydrolysis was
linear with respect to the incubation time and the amount of cytosolic proteins added,
PDE activities were measured with less than 30% of the total cAMP hydrolysed
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(Figure 1). For kinetic studies, total cAMP hydrolysed was kept below 15%. PDE





Time-course andprotein-dependence of the PDE activity
in AtT20 cells
Figure 1: PDE activity in AtT20 cytosol were measured with 1 pM cAMP as
substrate and in the presence of 100 pM Ca2+ and 100 nM CaM using the ZnSC>4-
Ba(OH)2 precipitation PDE assay. (A) For the time-course, aliquots of 10 pg
AtT20 cytosol were incubated for 5 to 45 min at 30 C. (B) For the protein-
dependence assessment, 2 to 32 pg AtT20 cytosol were incubated for 10 min at
30 . The PDE activity measured are expressed as a percentage of total cAMP (1
pM) hydrolysed. Data from one experiment representative of two performed are
shown. The data plotted are mean±S.D. ofPDE assay triplicates.
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2.8.2 QAE-Sephadex column method
The ZnS04-Ba(0H)2 precipitation method for PDE assay was compared to another
PDE assay method which employs chromatographic separation of cyclic nucleotides
and nucleosides on a column of an anion exchange resin, diethyl [2-
hydroxypropyljaminoethyl (QAE) A-25 Sephadex. In the QAE-Sephadex column
method, 3El-5'-nucleotides generated by PDE are further converted to 3H-nucleosides
by excess 5'-nucleotidase present in snake venom. The unreacted cyclic nucleotides
are bound to the QAE-Sephadex resin, while the nucleosides and their catabolites are
collected in the eluate for scintillation counting. The QAE A-25 Sephadex column
method was carried out according to a published protocol [209]. Briefly, QAE-
Sephadex A-25 (Sigma Q-25-120) in the chloride form was converted to the formate
form before being packed into the Bio-Spin chromatography column (6x15 mm,
Bio-Rad). The PDE assay buffer and the initiation of reaction were as for the
ZnS04-Ba(0H)2 precipitation method. The PDE reaction was terminated by the
addition of 50 pi normalised 0.2 N HC1. After neutralisation with 50 pi normalised
0.2 N NaOH, 50 pi of 1 mg/ml snake venom (Sigma V7000) was added and the
mixture incubated at 30 C for 10 min. The nucleotidase reaction was terminated
with a stop buffer containing 120 mM EDTA, pH 7.0, and 0.8 mM adenosine. 350
pi of the PDE assay mixture was then applied to the QAE-Sephadex column
previously equilibrated with 3 ml of 30 mM ammonium formate, pH 6.0. The eluate
together with that from two additional 1 ml washes with 30 mM ammonium
formate, pH 6.0, were collected in the same scintillation vial and counted with 15 ml
of Emulsifier-SAFE™ scintillation cocktail. The QAE-Sephadex column was
regenerated with 2 x 1 ml 0.2 N HC1, followed by 3 x 1 ml 30 mM ammonium
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formate, pH 6.0. The blank was less than 3 % of the total 3H-cAMP added. The
radioactivity of H-cAMP added was completely recovered in the eluate when excess
PDE activity from rat brain cytosol was used to completely hydrolyse cAMP.
2.8.3 Assay conditions for measuring the activity of different PDE
isozymes
The total PDE activity was taken as the activity measured in the presence of 100 pM
Ca2+ and 100 nM CaM (Sigma P2277). No further increase in PDE activity was
measured with up to 500 pM Ca2+ and 500 nM CaM. Ca2+/CaM-independent
2"E
activity was assayed in the presence of 0.5 mM EGTA. Ca /CaM-dependent
94-
(PDE1) activity was taken as the difference between the total and Ca /CaM-
independent PDE activities. PDE4 activity is defined as the activity measured with
0.5 mM EGTA that was inhibited by 10 pM rolipram. For the CaM dose response
studies of AtT20 cytosolic PDE1 activity, the endogenous CaM content in the cell
extracts was determined using activator-deficient bovine brain PDE1 (Sigma P9529).
Using 10 pM cAMP as substrate, the PDE activity of the activator-deficient PDE1
was measured in the presence of 0.1 - 100 nM CaM to obtain a CaM standard curve
and with aliquots of heat-inactivated (10 min in a boiling water bath) AtT20 cell
extracts. The endogenous CaM content in the cell extracts were then extrapolated
from the CaM standard curve based on the extent of stimulation of the activator-
deficient PDE1 activity by the heat-inactivated cell extracts.
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2.8.4 Verification of the ZnS04-Ba(0H)2 precipitation PDE assay
Under the conditions of the ZnS04-Ba(0H)2 precipitation method described above,
97±0.1% of 3H-AMP (n=24), 0.6±0.01% of 3H-cAMP (n=12) and 1.7±0.01% of 3H-
adenosine (n=8) were precipitated in the presence of up to 3 pM of the respective
unlabelled nucleotides (data are mean±S.E.M. of n separate determinations),
indicating highly selective separation cAMP from 5'-AMP. As reported previously
[208, 210, 211], adenosine was not precipitated with BaSC>4. Because 5'-AMP can
be further converted to adenosine by nucleotidase and/or phosphatase activities
present in cell extracts [212], the extent of this interference which may lead to an
underestimation of PDE activity was assessed. Firstly, PDE activity in AtT20
cytosol measured by the ZnS04-Ba(0H)2 precipitation assay or with the QAE-
Sephadex column method [209] (which allows separation of both 5'-AMP and
adenosine from cAMP) was near identical (Table 2). Secondly, PDE activity in
AtT20 cytosol measured with the ZnS04-Ba(0H)2 precipitation assay with or
without 1 mM AMP supplement (that have been used to minimise nucleotidase
interference [212-214]) was not significantly different, whereas 1 mM AMP
markedly reduced nucleotidase interference when rat brain extracts were used (Table
2). Thirdly, parallel time-courses of PDE and 5'-nucleotidase ( H-cAMP was
replaced with 3H-AMP) activities in AtT20 cell extracts indicated that less than 0.3%
of 3H-AMP was hydrolysed by 30 min, where up to 30% of 3H-cAMP was
hydrolysed. Hence, the further conversion of 5'-AMP to adenosine in AtT20 cytosol





Verification of the ZnS04-Ba(0H)2precipitation PDE assay
QAE-Sephadex ZnSC>4-Ba(OH)2
+ 1 mM AMP
Cytosolic protein (pg) (% of total cAMP hydrolysed)
2 2 ±0.3 3 ±0.3 3 ±0.1
4 7 ±0.4 7 ±0.2 6 ±0.2
8 11 ±0.3 14 ±0.7 11 ±0.2
16 23 ± 0.7 26 ±0.5 21 ±0.4
32 45 ±2.0 47 ± 0.5 42 ± 1.2
Rat brain cytosol 88 ±0.6 9 ±0.3 * 81 ± 1.5
(50 pg)
Table 2: PDE activity of AtT20 cytosol (2-32 pg) and rat brain homogenates (50
pg) were measured at 30°C for 10 min using the QAE-Sephadex method and the
BaSC>4 co-precipitation method with or without 1 mM AMP in the PDE assay buffer
(as described in section 2.8). Data are mean±S.E.M. of 3 separate determinations. *,




2.9.1 Design of primers for RT-PCR analysis of PDE1 and PDE4
isozymes
Primers were designed based on the available PDE sequences in the Genbank™ with
the aid of GeneJockey II (Biosoft, UK) and Amplify version 1.215 (University of
Wincosin, USA) softwares. The generic antisense primers, pdelr and pde4r, were
designed to amplify regions common to all known isozymes/splice variants of the
three-gene (PDE1A-C) PDE1 family and the four-gene (PDE4A-D) PDE4 family,
respectively (Figure 2). The sense primers, pdelaf, pdelbf and pdelcf, and the
antisense primers, pdelcr and pdelcr(2), were designed to amplify and distinguish
between the PDE1A, PDE1B and PDE1C isozymes (Figure 2). The splice-variant-
specific primers were designed based on differences in the 5' (pdelc2, pdelcl45,
pde4a5 and pde4d3) or 3' (pdelc45r) sequences of the known splice variants (Figure
2). All primers were synthesized by Cruachem, Todd Campus, Glasgow, Scotland,




Schematic representation showing the regions usedfor
designing RT-PCR primers
Figure 2: A schematic diagram showing the regions of representative PDE1 and
PDE4 isozymes used for designing RT-PCR primers. Primers were designed
based on the conserved regions within each family (hatched box), or isozyme
(gene)-specific regions (solid box), or splice variant-specific regions (arrow).
The name and Genbank™ accession number of the PDE isozymes used for this





Sequence information ofprimers usedfor RT-PCR analysis























Table 3: Sequences of primers (5'-3') designed to be used in the RT-PCR analysis





Total RNA was prepared from AtT20 cells and anterior pituitary glands using
TRIzol® reagent (GIBCO Life Sciences, Paisley, UK) according to the
manufacturer's instructions. First strand cDNA was synthesised from total RNA
using SUPERSCRIPT™ preamplification system (GIBCO). Briefly, 5 pg of total
RNA was heated with 2.5 pM random hexamers to 70 C for 10 min and quickly
chilled on ice. 10 units of SUPERSCRIPT II™ reverse transcriptase were added to
start first-strand cDNA synthesis at 42 C for 50 min in a 20-pl reaction volume
containing IX first strand buffer, 10 mM DTT and 0.5 mM dNTP mix. The reaction
was terminated by heating at 70 C for 15 min and aliquots of the cDNA were stored
at -40 C. PCR was carried out in a 50-pl reaction volume containing 1 pi of cDNA,
0.1-0.5 pM primers, 20 mM Tris-HCl, pH 8.0, 50 mM KC1, 2 mM MgCl2 and 0.2
mM dNTP mix. After heating the mixture to 95 C for 5 min, the PCR was initiated
by the addition of 2.5 units Taq DNA polymerase (GIBCO) at 80 C, followed by
denaturation at 95 C for 1 min, annealing at 60 C for 1 min, extension at 72 C for
3 min, for 35 cycles and a final 10 min of extension at 72 C. PCR primers were
tailed at the 3'-end in order to optimise for adenylation [215] and thus facilitate T/A
ligation. PCR products that corresponded to the expected size (visualised with
ethidium bromide under uv light) were purified using the Wizard PCR Prep kit
(Promega) or QIAEX II gel extraction kit (Qiagen, West Sussex, UK) before ligation
into pGEM®-T or pGEM®-T Easy vectors (Promega) according to the manufacturer's
instructions. The ligated plasmid was used to transform JM109 high efficiency
competent cells (Promega). Plasmid DNA prepared from antibiotic resistant
colonies was extracted using a Plasmid Mini kit (Qiagen), and the insert was
40
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sequenced in both directions using the Applied Biosystems Taq DyeDeoxy™
terminator cycle kit and model 373 DNA sequencer.
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2.10 Treatment with PKA catalytic subunit under phosphorylating
conditions in cell-free systems.
AtT20 cytosolic fractions or anion-exchange chromatographic fractions were
incubated at 30 C in a phosphorylation reaction buffer containing 30 mM Tris-HCl,
pH 7.5, 20 mM MgSCE, 0.5 mM ATP with or without PKA catalytic subunit. The
final concentration ofPKA catalytic subunit in the phosphorylation reaction was kept
below 1 pM according to the reported concentrations found in various tissues [216].
The incubation time and the amount of PKA catalytic subunit used are indicated in
the relevant figure legends. The phosphorylation reaction was terminated by the
addition of 0.1 pM protein kinase A inhibitor peptide [217] and by placing the tubes
on ice bath.
2.11 Anion-exchange chromatographic separation of PDE activities
DEAE-cellulose (DE-52 from Whatman) was used to pack a 9 mm x 15 cm column
(Pharmacia K9/15 column). The column was equilibrated with the starting buffer
containing 50 mM sodium acetate, pH 6.5, 0.1 mM EGTA, 5 mM |3-
mercaptoethanol, 10 mM NaF, 1 mM EDTA, 0.5 mg/L leupeptin, 0.7 mg/L
pepstatin, and 0.2 mM PMSF. Typically, 2 ml of the cytosolic fraction
(approximately 2 mg protein) was loaded and the column was washed with 2-column
volumes of starting buffer. The column was then eluted with a linear 0.05-1 M
sodium acetate gradient. 6 min (about 2 ml) fractions were collected and 10 or 20 pi
of each fraction was assayed for PDE activity with 1 pM cAMP as mentioned above
in the PDE assay. All chromatographic steps were carried out at 4°C.
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2.12 Antibodies selective for PDE4 subfamily
The rabbit polyclonal antibodies, Ab651 (anti-PDE4A) and Ab313 (anti-PDE4D),
the anti-VSV monoclonal antibody (anti-VSV), and the expression plasmid, pCI-
HSPDE4D3-VSV, were generously supplied by Prof. M. Houslay, University of
Glasgow, Scotland, UK. Ab651 was raised to a peptide sequence that corresponds to
amino acids 788-886 of human PDE4A5 (a common PDE4A C-terminal region) and
recognises all the known PDE4A splice variants [218], Ab313 was raised to the C-
terminal 40 amino acids of PDE4D2 (a common PDE4D C-terminal region) and
recognises all the five PDE4D splice variants known [109]. Anti-VSV recognises
the five C-terminal amino acids (507-511) of the vesicular stomatitis virus (VSV)
glycoprotein [219] that are part of the 11-amino acid VSV epitope tagged to the
recombinant human PDE4D3 in the pCI-HSPDE4D3-VSV plasmid [109],
The rabbit polyclonal antibody, AC55 (anti-PDE4A), the monoclonal antibody,
M3S1 (anti-PDE4D), and the recombinant rat PDE4D3 purified from baculovirus
expression in Sf9 insect cells were generously supplied by Prof. M. Conti, Stanford
University, USA. The characterization of these antibodies [220] and the
recombinant rat PDE4D3 [221] have been published.
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2.13 Immunoprecipitation of PDE4
For each immunoprecipitation reaction, 50 pi of a 20% Protein G-sepharose 4B
(Sigma P-3296) suspension (in 20% ethanol) was washed twice (pelleting at lOOOOg
for 15 s between washes) with phosphate-buffered saline (PBS) containing 0.1%
BSA (PBS-B) and then incubated with 5 pi of antibody in a final volume of 50 pi
(1:10 dilution in PBS-B) for lh at 4 C with end-on-end mixing. Normal rabbit
serum (NRS) at 1:10 dilution and BSA (0.1%) were used as controls in place of
polyclonal and monoclonal antibodies respectively. The beads were washed three
times with PBS-B and then incubated with the cytosolic extracts (50-500 pi or 0.1-1
mg cytosolic protein) for 1.5 h at 4 C with end-on-end mixing. At the end of the
incubation, the immunoprecipitation mixture was centrifuged at lOOOOg for 1 min to
obtain the supernatant and the immunoprecipitate. The supernatant was collected for
PDE assay. The immunoprecipitate was washed twice with PBS-B and once with
PBS, and then either resuspended in HB (to the same volume as the supernatant) for
PDE assay or resuspended to lx Laemmli's sample buffer (62.5 mM Tris-EICl, pH
6.8, 10% glycerol, 2% SDS, 5% B-mercaptoethanol, and 0.0025% bromophenol blue
[222]) and incubated in a boiling water bath for 3 min before subjected to SDS-
PAGE. Complete immunoprecipitation of the PDE4s from the cytosolic extracts was
indicated by two observations: 1. No further PDE4 activity was being pulled down
with twice the amount of antibodies (10 pi), and 2. The amount of PDE4 activity
pulled down was proportional to the amount (up to 1 mg cytosolic protein) of
cytosolic extracts used for the immunoprecipitation.
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2.14 SDS-PAGE and immunoblot analysis
Immunoprecipitated samples were electrophoresed on 8% SDS-polyacrylamide gel
at 30 V for 9 h (model V-16-2 vertical gel system from GIBCO BRL) or 150 V for 1
h (mini-PROTEAN II system from BIO-RAD). The electrophoresis buffer contained
25 mM Tris base, 192 mM glycine and 0.1% SDS (pH 8.3). SDS-electrophoresis
calibration kit containing both high (53-212 kDa) and low (14.4-94 kDa) molecular
weight markers was used for the calibration of the apparent molecular weights of the
separated proteins. 10 ng of recombinant rat PDE4D3 was also included in each run
to serve as a positive control for the immunodetection and for comparison with the
migration of immunoreactive bands. After electrophoresis, the separated proteins
were electroblotted (Trans-Blot cell from BIO-RAD) onto Immobilon membranes
overnight at 30 V, 4 C, in a transfer buffer containing 25 mM Tris base, 192 mM
glycine and 10% methanol. All subsequent membrane incubations were carried out
at room temperature in PBS containing 0.1% BSA and 0.1% Tween-20 (PBS-BT)
and the indicated reagents with shaking. After each incubation step, the membranes
were rinsed twice and washed three times (10 min per wash) with PBS-BT. The
membranes were first blocked in 5% BSA for 1 h, and then incubated with Ab313
(1:1000 dilution) for 1 h. The bound antibody was detected using HRP-conjugated
anti-rabbit IgG (1:5000 dilution for lhr) and the enhanced chemiluminescence (ECL)
detection system (Amersham, Little Chalfont, UK). After 1 min incubation in ECL




2.15 Transfection of HEK293 cells with recombinant HSPDE4D3
The expression plasmid, pCI-HSPDE4D3-VSV, which contains the cDNA encoding
human PDE4D3 fused with a C-terminal VSV epitope tag [109] was transfected into
HEK293 cells by the CaP04 method [223]. Briefly, HEK293 cells were plated at a
density of 105 cells/cm2 in 25 cm2 tissue culture flask 24 h before the transfection.
The CaPCVDNA coprecipitate was prepared by slowly adding 31 pi of 2 M CaCl to
a mixture consisted of 220 pi of plasmid DNA (i.e. pCI-HSPDE4D3-VSV, dissolved
in 1 mM Tris-HCl, pH 8.0, and 0.1 mM EDTA, to a concentration of 40 pg/ml) and
250 pi of 2X HEPES-buffered saline (50 mM HEPES, pH 7.05, 280 mM NaCl, 10
mM KC1, 1.5 mM Na2HP04 and 12 mM dextrose) with gentle shaking and was
further incubated for 30 min at room temperature. The CaP04-plasmid suspension
(500 pi) was then added to the medium above the HEK293 cells monolayer. The
next day, the medium containing the CaPC>4-plasmid coprecipitate was replaced with
fresh medium and the cells were grown for another three days before selecting for
neomycin-resistant stably transfected cells with 0.6 mg/ml Geneticin®. The VSV
epitope tagged HSPDE4D3 was immunoprecipitated with a monoclonal antibody




Data were evaluated by Student's /-test or 1-way ANOVA followed by Newman-
Keuls or Dunnett two-tailed tests as appropriate. Data of p<0.05 were considered
statistically significant. The apparent Km and Vmax values of the substrate saturation
studies were determined either by linear regression analysis of Eadie-Hofstee plot or
by one- and two-site models (fitted to the hyperbolic form of Michaelis-Menten
equation) with non-linear regression analysis and comparison of fits. The statistical
comparisons between one- and two-site fits were made by F-test. The apparent IC50
of PDE inhibitors, and the EC50 and Hill coefficient of CaM stimulation of PDE1
activity, were determined by fitting to a four-parameter logistic equation,
Y=Bottom+(Top-Bottom)/(l+10A((log(IC5o or EC5o)-X)(Hill coefficient)) with non¬
linear regression analysis, where Y=PDE activity, X=concentration of the modulator.
In the case of IC50 determination, the Top of the curve (which was the PDE activity
incubated with vehicle) was held constant. All curve fitting was carried using




3.1 Biochemical analyses of PDE activities
3.1.1 PDE activities in AtT20 cells
The first attempt was to distinguish cAMP-hydrolysing PDE activities in AtT20
whole cell homogenates by different PDE assay conditions. Using 1 pM cAMP as
substrate, PDE activity was found to increase about 2-fold when measured in the
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presence of excess Ca (100 pM) and CaM (100 nM) compared to that in the
presence of 0.5 mM EGTA (Figure 3A, WH columns). There was no further
9+
increase in PDE activity with up to 500 pM Ca and 500 nM CaM. The increased
PDE activity in the presence of 100 pM Ca2+/100 nM CaM was defined as the
Ca2+/CaM-stimulated PDE1 activity and was calculated from the difference between
the total PDE activity (measured with lOOpM Ca2+/100 nM CaM) and the Ca2+/CaM-
independent PDE activity (measured with 0.5 mM EGTA). Therefore the total PDE
i
activity can be broadly separated into PDE1 activity and Ca /CaM-independent
PDE activity. To determine the subcellular distribution of the two PDE activities,
the whole homogenate was first subjected to centrifugation at 200g for 10 min to
obtain the 200g pellet and the resulting supernatant was further centrifuged at
30000g to obtain the 30000g particulate fraction and the cytosolic fraction (i.e. the
30000g supernatant). When PDE activities in these fractions were measured
(standardised to the starting whole homogenate volume), more than 90% of PDE1
9+
and about 50% of Ca /CaM-independent PDE activity in the whole cell homogenate
were recovered in the cytosolic fraction (Figure 3A). Data pooled from several
experiments showed that the PDE1 activity constituted 73±2% (mean±S.E.M., n=10)




remaining Ca /CaM-independent PDE activity was inhibited by 10 pM rolipram, a
PDE4-selective inhibitor (i.e. about 20% of the total cytosolic PDE activity was
attributable to PDE4). As treatment of intact cells with a PDE-resistant and cell
permeable cAMP analogue, CPT-cAMP, specifically increased Ca2+/CaM-
independent PDE activity and reduced PDE1 activity in the cytosolic fraction (Figure
3B), subsequent analyses were focused on the cytosolic PDE activities.
3.1.1.1 Substrate saturation studies of PDE activities in the
cytosolic fraction
2_|_
To assess the properties of the cytosolic PDE1 and Ca /CaM-independent PDE
activity with respect to cAMP, substrate saturation experiments were performed with
0.25 to 100 pM cAMP (Figure 4). The Km and Vmax values were obtained by linear
regression of Eadie-Hofstee plots: PDE1 activity, Km = 0.89±0.29 pM and Vmax =
0.50±0.05 nmol/min/mg (mean±S.E.M., n=6); Ca2+/CaM-independent PDE activity,
Km = 1.02±0.15 pM and Vmax = 0.25±0.05 nmol/min/mg (mean±S.E.M., n=5).






in control and CPT-cAMP-treatedAtT20 cells
Figure 3: AtT20 cells were incubated with vehicle (A) or 1 mM CPT-cAMP (B)
for 10 min at 37 C. After treatment, cells (lOxlO6 per group) were lysed by
freeze-thawing in 500 pi homogenization buffer to give the whole homogenate
(WH). 250 pi of the WH was then centrifuged to obtain the 200g pellet (200g-
P), the 30000g particulate fraction (30000g-P) and the 30000g cytosolic fraction
(CF). The 200g-P and PF were resuspended to 250 pi with the homogenization
buffer and equal volumes (10 pi) ofWH, 200g-P, PF, and CF were measured for
• • • ? I
PDE activities in the presence of 0.5 mM EGTA (empty bar) or 100 pM Ca and
100 nM CaM to access the Ca2+/CaM-stimulated PDE1 activity (shaded bar).





Substrate saturation studies ofPDE activities in AtT20 cytosol
Figure 4: (A) PDE1 (empty circles) and Ca2+/CaM-independent PDE (filled
circles) activities in AtT20 cytosol were measured in the presence of 0.25-100
pM cAMP. Results of a representative experiment of six are shown (points are
means of triplicate PDE assay±S.D.). In this experiment, the apparent Km and
Vmax values calculated from linear regression of the Eadie-Hofstee plot (insert)
are: PDE1 activity (Km = 0.6 pM, Vmax = 0.7 nmol/min/mg protein); Ca2+/CaM-
independent PDE activity (Km = 1.4 pM, Vmax = 0.4 nmol/min/mg). Data from
six experiments are summarized in section 3.1.1.1.
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3.1.1.2 Pharmacological studies of PDE activities
The inhibition of the two cytosolic PDE activities by various PDE inhibitors were
assessed in the presence of 1 pM cAMP as substrate (Figure 5). The non-selective
PDE inhibitor, 3-isobutyl-l-methylxanthine (IBMX), was found to inhibit
completely both the Ca /CaM-independent and -stimulated PDE activities, with
similar apparent IC50 values of 12±1 and 15±2 pM (mean±S.E.M., n=3) respectively
(Figure 5). However, the inhibition profiles of the two PDE activities by more
2_|_selective PDE inhibitors were very different. Notably, about 60% of the Ca /CaM-
independent PDE activity was selectively inhibited by rolipram (a specific inhibitor
of PDE4) with an apparent IC50 value of 0.11±0.03 pM (mean±S.E.M., n = 9), while
the Ca2+/CaM-stimulated PDE activity was not inhibited by up to 100 pM rolipram
(Figure 5). A derivative of IBMX, 8-methoxymethyl-3-isobutyl-l-methylxanthine
(8-MIX), which is known to selectively inhibit PDE1 [224-226] and Zaprinast, a
PDE5-selective inhibitor that has also been shown to inhibit PDE1 [226, 227], were
considerably more potent inhibitors of the Ca2+/CaM-stimulated PDE activity than of
the Ca2+/CaM-independent PDE activity (Figure 5). The apparent IC50 values of 8-
MIX and Zaprinast for the Ca2+/CaM-stimulated PDE activity, 10±2 and 7±1 pM
(mean±S.E.M., n=3) respectively, were similar to those reported for PDE1 isozymes
[84]. Vinpocetine, which had been reported to be selective for PDE1 in some studies
[49, 226, 228] but not all [229], was observed to inhibit both PDE activities in AtT20
cells with similar potency (Figure 5); apparent IC50 values were 62±3 pM for
Ca2+/CaM-independent PDE activity and 65±3 pM for PDE1 activity (mean±S.E.M.,
n=3). Taken together, the pharmacological analysis supported the presence of PDE1




Inhibition ofPDE activities in AtT20 cytosolicfraction
by known PDE inhibitors
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Figure 5: Ca2+/CaM-independent (A) and -dependent (B) PDE activities in the
cytosolic fraction of AtT20 cell homogenate were assayed with 1 pM cAMP as
substrate and in the presence of vehicle (0.1% DMSO) or PDE inhibitors. Data
plotted are mean±S.E.M., n=3 separate determinations. The apparent IC50 values




3.1.1.3 Separation of PDE activities by DEAE-cellulose
chromatography
Anion exchange chromatography has been shown to effectively separate PDE1 from
PDE4 activity, and from its endogenous activator, CaM [74, 230-232], As the
cAMP-hydrolysing activity in AtT20 cytosolic fraction was mainly contributed by
PDE1 and PDE4 isozymes, DEAE cellulose chromatography was used to separate
these isozymes for further analysis. Two distinct peaks of PDE activity were
obtained when AtT20 cytosolic fraction was eluted with a linear sodium acetate
gradient (0.05-1 M) on a DEAE cellulose column (Figure 6A). PDE activity of peak
9+
1 (eluting at 0.1-0.2 M sodium acetate) was Ca /CaM-stimulated while that of peak
2 (eluting at 0.4-0.5 M sodium acetate) was Ca2+/CaM-independent and was largely
inhibited by 10 pM rolipram. The PDE1 activity in peak 1 was then subjected to
• 9 I
substrate saturation analysis (0.25-1 OOpM cAMP) in the presence of 100 pM Ca
and 100 nM CaM (Figure 6B). Eadie-Hofstee plots from 5 out of 7 experiments
suggested a single component of PDE1 activity with an apparent Km of 0.54±0.06
pM and Vmax of 2.4±1.1 nmol/min/mg protein (mean±S.E.M., n=5). In the
remaining 2 experiments, the data best fitted to two-site model (F<0.01) with an
additional high Km component of apparent Km = 20 and 30 pM, and Vmax = 4.7 and
1.9 nmol/min/mg protein respectively. In sum, DEAE cellulose chromatographic
separation of cAMP-hydrolysing PDE activities in AtT20 cytosolic fraction indicated




DEAE-cellulose chromatographic separation ofPDE activities
in AtT20 cell cytosol
o
Figure 6: (A) Cytosolic fraction prepared from about 10 cells was used for each
separation. 2 ml fractions were collected over a linear 0.05-1 M sodium acetate
(pH 6.5) gradient. 20 pi of each fraction was assayed for PDE activity under 3
conditions: 100 pM Ca2++100 nM CaM (shaded diamonds), 0.5 mM EGTA
(empty triangles) and 0.5 mM EGTA+10 pM rolipram (empty circles). The
elution profde shown is representative of 7 similar runs. (B) Eadie-Hofstee plot
of peak 1 PDE activity measured with 0.25-100 pM cAMP in the presence of 100
•"i |
pM Ca and 100 nM CaM. The mean Km and Vmax values from 7 separate
experiments are summarised in section 3.1.1.3.
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3.1.2 PDE activities in rat anterior pituitary
Both PDE1 and Ca /CaM-independent PDE activities were also detected in rat
adenohypophysis crude homogenates with 1 pM cAMP as substrate. The proportion
and distribution of the two activities were similar to that found in AtT20 cells: all the
94-
PDE1 and about 60% of the remaining Ca /CaM-independent PDE activity were
recovered in the cytosolic fraction; with PDE1 constituting 71±3% and 81±2% of the
total PDE activity in the whole homogenate and the cytosolic fraction respectively
(mean±S.E.M, n=3). Of the remaining Ca2+/CaM-independent PDE activity, 67±2%
and 56±1% was inhibited by 10 pM rolipram in the whole homogenate and the
cytosolic fraction respectively (mean±S.E.M., n=3), i.e. about 10-20% of the total
adenohypophysial PDE activity was attributable to PDE4. In two experiments using
the cytosolic fractions, the apparent IC50 values of rolipram were 0.14 and 0.39 pM.
3.1.2.1 Separation by DEAE-chromatography
When the rat anterior pituitary cytosolic fractions were subjected to DEAE-cellulose
chromatography, a sharp peak ofPDE activity (peak 1) eluting at 0.05-0.1 M sodium
acetate, followed by a broad shoulder (0.1-0.4 M sodium acetate), which were
stimulated at least 4- and 2.5-fold, respectively, by 100 pM Ca2+/100 nM CaM were
obtained (Figure 7A). Under these conditions, rolipram-sensitive PDE activity was
not readily detected. Substrate saturation analysis of peak 1 with 0.25-100 pM
cAMP and 100 pM Ca2+/100 nM CaM indicated the presence of low and high Km
PDE1 activities (Figure 7B). The mean Km values from 3 separate experiments
determined by non-linear regression analysis using a two-site model were 0.36±0.11
and 53±12 pM (p<0.05, two-tailed unpaired t-test), with Vmax values of 0.56±0.12
56
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and 20±8 nmol/min/mg respectively (mean±S.E.M, n=3). These kinetic results
indicated the presence of low Km, low capacity as well as high Km, high capacity




DEAE-cellulose chromatographic separation ofPDE activities
in rat anteriorpituitary cytosol
Figure 7: (A) For each separation, cytosolic fraction prepared from the anterior
pituitary glands of 4 Wistar rats was used. Fractions were collected and analysed
as in AtT20 cells (Figure 6). The activity profile shown is representative of 3
similar runs. (B) Eadie-Hofstee plot of PDE1 activity in the sharp peak eluting at
0.05-0.1 M sodium acetate. PDE1 activity was assayed in the presence of 100
pM Ca2+ and 100 nM CaM with 0.25-100 pM cAMP as substrate. The Km and
Vmax values were determined by non-linear regression using a 2-site model. In
this experiment : Km' = 0.18±0.21 pM and Km2 = 34±0.4 pM, with Vmax1 =
0.39±0.11 and Vmax2 = 7.4±0.2 nmol/min/mg respectively (estimated value±S.E.).




3.2 RT-PCR analysis of PDE isozyme expression
As the biochemical and pharmacological analyses suggested that the main cAMP-
hydrolysing activity in AtT20 cells and rat adenohypophysis was contributed by
PDE1 and PDE4 isozymes, the expression of these isozymes was examined by RT-
PCR analysis. A list of the primer pairs used and a summary of the results obtained
is given in Table 4.
3.2.1 PDE1 mRNAs in AtT20 cells
Three distinct genes code for PDE1A, PDE1B and PDE1C (Figure 2). RT-PCR
performed using total RNA extracted from AtT20 cells with gene-specific sense
primers, pdelaf, pdelbf and pdelcf, and a generic PDE1 antisense primer, pdelr,
generated RT-PCR products of the expected size (Table 4 and Figure 8, lane a-c).
Although the RT-PCR product corresponding to PDE1A (Figure 8, lane a) could not
be subcloned after several attempts, that from the mouse anterior pituitary was
subsequently sequenced and identified with mouse PDE1A (see section 3.2.3). The
sequence obtained from the RT-PCR product corresponding to PDE IB (Figure 8,
lane b) was identified as mouse PDE1B (Table 4). With respect to the identification
of PDE1C isozymes, further RT-PCR was carried out to explore the expression of
various splice variants, namely PDE1C1, PDE1C2 and PDE1C4/5 (Figure 2). A 2-
kb PCR product was obtained using splice variant-specific primers, pdelcl45f and
pdelc45r (Figure 8, lane c), the nucleotide sequence of which matched the complete
coding sequence ofmouse PDE1C4/5 (Table 4). Thus the expression of PDE1B and
PDE1C4/5 in AtT20 cells at the mRNA level were detected.
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3.2.2 PDE4 mRNAs in AtT20 cells
The expression of PDE4 isotypes in AtT20 cells was analysed with a similar
approach as for PDE1. Four genes are known to code for PDE4A, PDE4B, PDE4C
and PDE4D, each of which is known to give rise to splice variants. As there was
limited mouse PDE4 sequences available, the RT-PCR primers were designed based
on the rat sequences in the GenBank™ database (Figure 2). RT-PCR analyses using
gene- and splice variant-specific sense primers, pde4a5f and pde4d3f, with a generic
PDE4-specific anti-sense primer, pde4r, have confirmed the expression of PDE4A5
and PDE4D3 in AtT20 cells (Figure 8, lane d and f, respectively, and Table 4). The
expression of PDE4D3 was also demonstrated using the pde4d3f sense primer with
a PDE4D-specific anti-sense primer, pde4dr (Figure 8, lane g and Table 4). RT-PCR
product amplified using the PDE4B gene-specific primers, pde4bf and pde4br, was
sequenced to match the core nucleotide and amino acid sequences of rat PDE4B
(Figure 8, lane e and Table 4). No RT-PCR product was obtained using the PDE4C
gene-specific primer, pde4cf and pde4cr (Table 4). Thus, RT-PCR analysis have
confirmed the expression of multiple PDE4 isozymes in AtT20 cells, specifically
mRNAs coding for PDE4A5, PDE4B and PDE4D3 were detected.
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3.2.3 PDE1 and PDE4 mRNAs in rat and mouse anterior pituitaries
A similar approach of RT-PCR analysis as described for AtT20 cells was used to
examine the expression of PDE1 and PDE4 isozymes in rat anterior pituitary. The
expression of PDE1C (Figure 8, lane h, with primers pdelcf and pdelcr), PDE4B
(Figure 8, lane i, with primers pde4bf and pde4br) and PDE4D3 (Figure 8, lane j,
with primers pde4d3 and pde4dr) were detected and confirmed by sequencing the
RT-PCR products (Table 4). As the PCR product corresponding to PDE1A could
not be subcloned from the AtT20 cells, RT-PCR was performed using mouse
anterior pituitary and with primers, pdelAf and pdelr, for verification (Figure 8, lane
k). The RT-PCR product obtained was subcloned and sequenced to match mouse
PDE1A (Table 4). RT-PCR product corresponding to PDE1C4/5 was also obtained
with mouse anterior pituitary using primers, pdelcl45f and pdelc45r (Figure 8, lane
1).
In summary, the RT-PCR analysis indicated the expression of multiple isozymes of
the PDE1 and PDE4 families in AtT20 cells as well as rat anterior pituitary gland.
Specifically, evidence for the expression of low Km PDE1 variants derived from the
PDE1C gene and of the cAMP-specific PDE4s, PDE4B and PDE4D3, was found in
both AtT20 cells and rat anterior pituitary gland. In addition, the expression of
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pdelaf pdelr 971 RT-PCR products obtained with AtT20 (Fig. 8a) and
mouse AP (Fig. 8k). Sequence ofmouse AP RT-PCR
product matched the conserved region ofmouse PDE1A
variants.
No RT-PCR product detected with Rat AP.
pdelbf pdelr 841 Sequence ofAtT20 RT-PCR product (Fig. 8b) matched the
conserved region mouse PDE1B variants.





RT-PCR product obtained with AtT20.
RT-PCR products obtained with AtT20 and rat AP (Fig.
8h). Sequence of rat AP RT-PCR product matched the
conserved region of rat PDE1C variants.





No RT-PCR product detected with rat AP.





RT-PCR product obtained with AtT20.
RT-PCR product obtained with AtT20 (Fig. 8c) and mouse
AP (Fig.81).
Sequence ofAtT20 RT-PCR product matched mouse
PDE1C4/5 splice variants [L76946/7],
No RT-PCR product detected with rat AP.






pde4a5f pde4r 678 Sequence of AtT20 RT-PCR product (Fig. 8d) matched rat
PDE4A5 [L27056].
No RT-PCR product detected with rat AP.
pde4bf pde4br 339 Sequences of AtT20 and rat AP RT-PCR products (Fig. 8e
and 8i respectively) matched conserved region of rat
PDE4B variants.





Sequence ofAtT20 RT-PCR product (Fig. 8f) matched rat
PDE4D3 [U09547],
Sequences ofAtT20 and rat AP RT-PCR products (Fig. 8g
and 8j respectively) matched rat PDE4D3 [U09547].
Table 4: The primer pairs (see Table 3 for sequence information) used to detect the
mRNAs of PDE 1 and PDE4 isozymes/splice variants in AtT20 cells, rat and mouse
anterior pituitary (AP), are tabulated together with the results obtained. The third
column indicates the expected size of specific RT-PCR product. Where RT-PCR
products were obtained, they were of the expected size and the respective lanes in
Figure 8 are shown in brackets. The DNA sequences obtained by subsequent
subcloning and sequencing were screened with both the GenBank™ non-redundant
nucleotide and protein sequence databases (using blastn and blastx programs
respectively). The top matches (93-100% identity with both databases) are shown





Figure 8: RT-PCR were performed using total RNA prepared from AtT20 cells,
rat anterior pituitary and mouse anterior pituitary (as described in section 2.9).
The primer pairs used to amplify the respective RT-PCR products are: a (pdelaf
+ pdelr); b (pdelbf + pdelr); c (pdelcl45f + pdelc45r); d (pde4a5f + pde4r); e
(pde4bf + pde4br); f (pde4d3f + pde4r); g (pde4d3f + pde4dr); h (pdelcf +
pdelcr); i (pde4bf + pde4br); j (pde4d3f + pde4dr); k (pdelaf + pdelr); 1
(pdelcl45f + pdelc45r). 5 pi of each RT-PCR reaction was analysed on a 0.8%
agarose gel. All RT-PCR products shown above, except that of lane a and 1, have
been subsequently subcloned and sequenced to match the PDE isozyme shown
below each lane. The sequence of the primers and the results obtained are
tabulated in Table 3 and 4 respectively.
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3.3 Regulation of PDE1 and PDE4 activities by cAMP-dependent
phosphorylation
3.3.1 Studies in intact cells
3.3.1.1 Activation of PDE4 by cAMP-dependent pathway
Incubation of AtT20 cells with 100 nM CRF resulted in a transient stimulation of
Ca2+/CaM-independent PDE activity that peaked at around 1 min (Figure 9), which
parallels the time-course of the cAMP response to CRF in these cells [180], In
AtT20 cells, the cAMP response to CRF is small and short-lived because of the rapid
hydrolysis of cAMP by PDEs. Application of the PDE-resistant cAMP analogue, 8-
(4-chlorophenylthio)-cAMP (CPT-cAMP), resulted in a dose-dependent (Figure
2+
10A) and rapid (within 2 min) enhancement of Ca /CaM-independent cAMP
hydrolysis, which was entirely blocked by 10 pM rolipram, indicating the activation
of PDE4 activity (Figure 10B). The effect of CPT-cAMP could be blocked by
preincubation of the cells with 30 pM H-89, a protein kinase A (PKA)-selective
inhibitor [233] (Figure 12A). This suggested that the activation of PDE4 activity in
AtT20 cells by CPT-cAMP is mediated by PKA. Treatment of AtT20 cells with 50
nM calyculin A, a protein phosphatase1/2A inhibitor, was also found to activate
PDE4 activity in a time-dependent manner (Figure 11). However, the activation of
PDE4 activity by calyculin A, which was usually to a greater extent (more than 2-
fold of control) compared to that by CPT-cAMP, was only partially inhibited by
preincubation with 30 pM H-89 (Figure 12B). In order to examine the relationship
between the effects of CPT-cAMP and calyculin A, time-courses of treatment with
CPT-cAMP and calyculin A in isolation and in combination on PDE4 activity were
compared (Figure 13). The results indicated significant additive effect of CPT-
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cAMP and calyculin A on the activation of PDE4 activity at 5 min, when the effect
of calyculin A alone was submaximal. As observed with calyculin A treatment
alone, the activation ofPDE4 activity by CPT-cAMP and calyculin A in combination
was only partially inhibited by preincubation with 30 pM H-89 (Figure 14B).
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Figure 9
Time course ofCRF activation ofCa /CaM-independent PDE activity
Figure 9: AtT20 cells growing on 24-well plates were incubated with 100 nM
CRF or vehicle at 24°C for different durations. Total cell extracts prepared from
each well by freeze-thawing in homogenisation buffer were assayed for PDE
activity in the presence of 0.5 mM EGTA. Data are mean±S.E.M., n = 4. *,
p<0.05 when compared with the control group in one-way ANOVA followed by
Dunnetf s two-tailed test.
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Figure 10
CPT-cAMP activation ofPDE4 activity in AtT20 cells
Results
Figure 10: (A) Concentration dependence of CPT-cAMP activation of
Ca2+/CaM-independent PDE activity. AtT20 cells were incubated with 0, 0.1, 1
and 2 mM CPT-cAMP at 37 C for 10 min. Ca2+/CaM-independent PDE activity
of the cytosolic fraction was assayed in the presence of 0.5 mM EGTA and
expressed as a percentage of control (incubation with vehicle) activity. Data are
mean±S.E.M., n = 3. (B) Time-course of 1 mM CPT-cAMP. AtT20 cells were
incubated with 1 mM CPT-cAMP at 37°C for 0, 2, 5 and 10 min and the
cytosolic fractions were assayed for Ca2+/CaM-independent PDE activity in the
presence of 0.5 mM EGTA with (empty circle) or without (shaded circle) 10 pM




Time-course ofCalyculin A activation ofPDE4 activity in AtT20 cells
Figure 11: AtT20 cells were treated with 50 nM calyculin A for 0, 2, 5, 10, 30 and
60 min at 37 C. After incubation, the Ca2+/CaM-independent PDE activity of the
cytosolic fraction was assayed in the presence of 0.5 mM EGTA with (empty circles)
or without (shaded circles) 10 pM rolipram. Data are mean±S.E.M., n=3.
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Figure 12
Inhibition ofCPT-cAMP and Calyculin A effect by H-89
Results
Figure 12: AtT20 cells were preincubated with vehicle (0.3% DMSO) or 30 pM
H-89 at 37 C for 10 min before the addition of (A) 1 mM CPT-cAMP or (B) 50
nM calyculin A for 10 min at 37 C. In (A) the Ca2+/CaM-independent PDE
activity of the cytosolic fraction was assayed in the presence of 0.5 mM EGTA
and expressed as a percentage of the control (preincubated with vehicle and no
CPT-cAMP treatment) PDE activity. In (B) the PDE4 activity was measured as
the Ca2+/CaM-independent PDE activity inhibited by 10 pM rolipram. Data are
mean±S.E.M., n = 3. *, p<0.05 when compared with the control group in one¬




Time course ofdifferential regulation ofPDE1 andPDE4
in AtT20 cells by CPT-cAMP and calyculin A
Figure 13: AtT20 cells were incubated with (A) 1 mM CPT-cAMP or (B) 50
nM calyculin A or (C) 1 mM CPT-cAMP and 50 nM calyculin A in combination
at 37 C for 5, 10 and 30 min. Data are mean±S.E.M., n=4. *, p<0.05, when
compared with respective control activity at time 0 in one-way ANOVA followed




H-89 inhibition ofCPT-cAMP and calyculin A effects
in AtT20 cells
Figure 14: AtT20 cells were preincubated with (empty triangles) or without
(shaded triangles) 30 pM H-89 at 37 C for 30 min before treatment with 1 mM
CPT-cAMP and 50 nM calyculin A in combination at 37 C for 5, 10 and 30
min. Cytosolic extracts from each time points were measured for (A) PDE1 and
(B) PDE4 activities. Data are mean±S.E.M., n=3/group. *, p<0.05 when
compared with control group at time 0. f, p<0.05 when compared with
corresponding control group at each time point without H-89 treatment.
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3.3.1.2 Inhibition of PDE1 by cAMP-dependent pathway
In contrast to PDE4, activation of cAMP-dependent pathway was found to inhibit
PDE1 activity. While treatment with CRF produced no consistent alteration of
PDE1 activity (data not shown), incubation with CPT-cAMP caused a significant
reduction in PDE1 activity (Figure 3 and 13A). Treatment of AtT20 cells with 50
nM calyculin A alone also resulted in a consistent time-dependent inhibition of
PDE1 activity (Figure 13B). Notably, treatment with CPT-cAMP and calyculin A in
combination synergistically inhibited PDE1 activity at 5 and 10 min (p<0.05) and
had additive effects at 30 min (Figure 13C). Importantly, treatment with H-89
markedly reduced the inhibition of PDE1 by CPT-cAMP and calyculin A at all time-
points examined (Figure 14A).
3.3.1.3 Inhibition of CaM stimulation of PDE1 by cAMP-
dependent pathway
The effect of CPT-cAMP and calyculin A on low Km PDE1 in AtT20 cells was to
reduce the maximal activation by Ca2+/CaM (control = 0.86±0.03 and CPT-
cAMP+calyculin A = 0.43±0.05 nmol/min/mg, mean±S.E.M., n=4, p<0.01, Student's
t-test), and to increase the apparent EC50 for CaM by approximately 5-fold (control
= 6.5±0.7 and CPT-cAMP+calyculin A = 36.6±6.9 nM, mean±S.E.M., n=4, p<0.01,
• • • • • 94-
Student's t-test )(Figure 15). The Hill-coefficient of activation by Ca /CaM was





PDE1 stimulation by CaM was markedly reduced
by CPT-cAMP and calyculin A treatment in intact AtT20 cells
Figure 15: Cytosolic fractions of AtT20 cells incubated with vehicles (shaded
circles) or ImM CPT-cAMP and 50 nM calyculin A in combination (empty
circles) for 10 min at 37 C were assayed for PDE1 activity in the presence of
100 pM Ca2+ and exogenous CaM up to 1 pM. The endogenous CaM content
estimated from standard curve using activator-deficient bovine brain PDE1
(Sigma P9529) with heat-inactivated (10 min in boiling water bath) cytosolic
fractions was about 0.1 pmol/pg protein, equivalent to about 1-2 nM in the PDE
assay reaction mix and was taken into account with the exogenously added CaM.
Data shown are mean±S.E.M. of 4 separate cell extracts. The kinetic parameters
determined by fitting these data to a 4-parameter logistic equation followed by




To investigate further the contribution of specific PDE4 isozymes to the AtT20
cytosolic PDE4 activity, antibodies selective for PDE4A and PDE4D isozymes were
used for immunoprecipitation studies. Of the control PDE4 activity, 57±3%
(mean±S.E.M., n=6) and 24±1% (mean±S.E.M., n=3) of the activity were
immunoprecipitated by a monoclonal PDE4D antibody, M3S1, and a polyclonal
PDE4A antibody, AC55, respectively. Importantly, more than 60% of PDE4 activity
activated by CPT-cAMP and/or calyculin A was immunoprecipitated by M3S1
(Figure 16), while a much smaller proportion (less than 15%) was
immunoprecipitated by AC55 (Figure 17). This indicated that the PDE4 activity




Immunoprecipitation ofPDE4 in AtT20 cells with M3S1
Results
Figure 16: AtT20 cells were treated with vehicle (0.05% EtOH), 1 mM CPT-
cAMP, 50 nM calyculin A, and 1 mM CPT-cAMP plus 50 nM calyculin A in
combination, for 10 min at 37 C. Aliquots of cytosolic fractions from each
treatment group were incubated with protein G-Sepharose preabsorbed with BSA
(0.1%) or M3S1 (5 pl/reaction) at 4 C for 1.5 h (as detailed in section 2.13).
After the incubation, the supernatant of the immunoprecipitation with BSA
(shaded bar) and M3S1 (hatched bars) was measured for PDE4 activity. The
immunoprecipitate (IP) from the BSA (empty bars, BSA-IP) and M3S1 (spotted
bars, M3S1-IP) incubation were washed and resuspended to equal volume to the
supernatant before measuring for PDE4 activity. Results from a representative




Immunoprecipitation ofPDE4 in AtT20 cells with AC55
Results
Figure 17: AtT20 cells were treated with vehicle (0.05% EtOH), 1 mM CPT-
cAMP, 50 nM calyculin A, and 1 mM CPT-cAMP plus 50 nM calyculin A in
combination, for 10 min at 37 C. Aliquots of cytosolic fractions from each
treatment group were incubated with protein G-Sepharose preabsorbed with NRS
(5 pl/reaction) or AC55 (5 pl/reaction) at 4 C for 1.5 h (as detailed in section
2.13). After the incubation, the supernatant of the immunoprecipitation with
NRS (shaded bar) and AC55 (hatched bars) was measured for PDE4 activity.
The immunoprecipitate (IP) from the NRS (empty bars, NRS-IP) and AC55
(spotted bars, AC55-IP) incubation were washed and resuspended to equal
volume to the supernatant before measuring for PDE4 activity. Results from a





M3S1 immunoprecipitates obtained from control and CPT-cAMP and/or calyculin
A-treated AtT20 cells were subjected to immunoblot analysis using the polyclonal
PDE4D antibody, Ab313, for detection. Two immunoreactive bands of apparent
molecular weight of 93±0.2 and 101±0.2 kDa (mean±S.E.M., n=3) were detected in
control AtT20 cytosolic fraction (Figure 18, lane 1). The 93 kDa band appeared to
co-migrate with the recombinant rat PDE4D3 (Figure 18, rPDE4D3). Importantly,
the migration of both bands in SDS-PAGE appeared to be retarded upon treatment
with CPT-cAMP, resulting in two distinct bands of 97±0.1 and 103±0.2 kDa
(mean±S.E.M., n=3)(Figure 18, lane 2), while calyculin A treatment (with or without
CPT-cAMP) resulted in multiple immunoreactive bands ranging from 93-111 kDa




Phosphorylation-induced mobility shift ofPDE4D splice variants
in AtT20 cells
Figure 18: AtT20 cells were treated with vehicle (Lane 1), 1 mM CPT-cAMP (Lane
2), 50 nM calyculin A (Lane 3), or 100 mM CPT-cAMP + 50 nM calyculin A (Lane
4) for 10 min at 37 C. Immunoprecipitates obtained by incubating the respective
cytosolic extracts (500 pg protein) with a PDE4D-specific monoclonal antibody,
M3S1, were electrophoresed on 8% SDS-PAGE. 10 ng of purified recombinant rat
PDE4D3 (rPDE4D3) was included for reference. Subsequent western blot was
visualised using a PDE4D-specific polyclonal antibody, Ab313, and the ECL
detection reagents (Amersham). Details of SDS-PAGE and western blotting
methods are described in Section 2.14. The mean apparent molecular weights of the
immunoreactive bands from 3 separate experiments and calculated from the standard
curve were: rPDE4D3 (93±0.1 kDa), Lane 1 (93±0.2 and 101±0.2 kDa), Lane 2
(97±0.1 and 103±0.2 kDa), Lane 3 (93-107 kDa) and Lane 4 (100-111 kDa).
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3.3.1.6 Regulation of recombinant PDE4D3 expressed in HEK293
cells
The effect of CPT-cAMP and calyculin A on PDE4 activity was also observed in
HEK293 cells (Figure 19A), suggesting the presence of mechanisms mediating CPT-
cAMP and calyculin A effects similar to that in AtT20 cells. In order to obtain
further support for the regulation ofAtT20 endogenous PDE4D3 by CPT-cAMP and
calyculin A, and to demonstrate if these regulations are common to other cell type, a
stably transfected HEK293 cell line (HEK293-4D3-VSV) was established to
overexpress a recombinant VSV-tagged human PDE4D3. The expression of VSV-
tagged HSPDE4D3 has been characterised in COS-1 cells and shown to be similar in
characteristics to its native counterpart [109, 234]. There was a 8-fold increase in
basal PDE4 activity of HEK293-4D3-VSV cells compared to that of normal
HEK293 cells (HEK293-4D3-VSV: 1.0±0.1 nmol/min/mg versus HEK293: 0.13±0.1
nmol/min/mg, mean±S.E.M., n=5 and 7, respectively), which was also activated by
CPT-cAMP and calyculin A (Figure 19B). The PDE4 activity activated by CPT-
cAMP was completely immunoprecipitated by the monoclonal antibody, anti-VSV,
which recognises the VSV epitope (Figure 20A). Notably, the PDE4 activity
activated by calyculin A treatment was largely but not completely
immunoprecipitated by anti-VSV (Figure 20B). Subsequent immunoblot analysis of
the anti-VSV immunoprecipitates using the polyclonal PDE4D antibody, Ab313, for
detection showed that the recombinant HSPDE4D3-VSV immunoprecipitated by
anti-VSV from control HEK293-4D3 cells migrated just behind the rat recombinant
4D3 (Figure 21, rPDE4D3) with an apparent molecular weight of 97±0.4 kDa
(mean±S.E.M., n=5) (Figure 21, lane 1), as reported [234], An additional
immunoreactive band of 102±0.6 kDa (mean±S.E.M., n=4) appeared upon treatment
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with CPT-cAMP alone (Figure 21, lane 2), while treatment with calyculin A alone or
in combination with CPT-cAMP resulted in multiple immunoreactive bands ranging




Activation ofPDE4 activity by CPT-cAMP and Calyculin A
in normal andPDE4D3-VSV-transfected HEK293 cells
Figure 19: (A) Normal and (B) HSPDE4D3-VSV-transfected HEK293 cells
were incubated with vehicle (0.05% ethanol), 1 mM CPT-cAMP, 50 nM
calyculin A, or 1 mM CPT-cAMP and 50 nM calyculin A in combination, for 10
min at 37 C. PDE4 activity in the cytosolic fraction was assayed. Data are




Immunoprecipitation ofPDE4 activity in PDE4D3-VSV-transfected
HEK293 cells with anti-VSVmonoclonal antibody
Figure 20: HEK293 cells transfected with HSPDE4D3 tagged with VSV epitope
were incubated with 1 mM CPT-cAMP (A) or 50 nM calyculin A (B) at 37 C
for 10 min. Aliquots of cytosolic fractions from each treatment group were
incubated with protein G-Sepharose preabsorbed with BSA (0.1%) or anti-VSV
(5 pl/reaction) at 4 C for 1.5 h (as detailed in Section 2.13). After the
incubation, the supernatant of the immunoprecipitation with BSA (shaded bar)
and anti-VSV (hatched bars) was measured for PDE4 activity. The
immunoprecipitate (IP) from the BSA (empty bars, BSA-IP) and anti-VSV
(spotted bars, anti-VSV-IP) incubation were washed and resuspended to equal
volume to the supernatant before PDE4 activity measurement. Data are




Phosphorylation-inducedmobility shift ofrecombinant HSPDE4D3
in stably transfectedHEK293 cells
Figure 21: HEK293 cells transfected with HSPDE4D3 tagged with VSV epitope
were treated with vehicle (Lane 1), 1 mM CPT-cAMP (Lane 2), 50 nM calyculin A
(Lane 3), or 1 mM CPT-cAMP + 50 nM calyculin A (Lane 4) for 10 min at 37 C.
Immunoprecipitates obtained by incubating the respective cytosolic extracts (100 pg
protein) with an anti-VSV monoclonal antibody were electrophoresed on 8% SDS-
PAGE. 10 ng of purified recombinant rat PDE4D3 (rPDE4D3) was included for
reference. Subsequent western blot was visualised using a PDE4D-specific
polyclonal antibody, Ab313, and the ECL detection reagents (Amersham). The
mean apparent molecular weights of the immunoreactive bands from 3-5
experiments and calculated from the standard curve were: rPDE4D3 (93±0.1 kDa,
n=3), Lane 1 (97±0.4 kDa, n=5), Lane 2 (102±0.6 kDa, n=4), Lane 3 (99-110 kDa)
and Lane 4 (99-110 kDa).
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3.3.2 Studies in cell-free system
3.3.2.1 Differential regulation of PDE1 and PDE4 activity by PKA
catalytic subunit
Incubation of AtT20 cytosolic fraction with PKA catalytic subunit under
phosphorylating conditions resulted in changes of PDE1 and PDE4 activities similar
to those induced by CPT-cAMP and calyculin A in intact cells (Figure 22). The
enhancement of Ca2+/CaM-independent PDE activity by PKA was fully inhibited by
10 pM rolipram, indicating selective activation of PDE4 (Figure 23). The specificity
of PKA action was indicated by blockade of the activation of PDE4 by adding 10
pM H-89 (not shown) or 0.1 pM PKA inhibitor peptide (PKI) (Figure 23) in the
phosphorylation reaction mixture.
The reduction of PDE1 activity by PKA catalytic subunit was further investigated
using peak 1 fractions (that contain partially purified PDE1) obtained from the
DEAE cellulose chromatographic separation (Figure 6A). As with the cytosolic
fraction, incubation of peak 1 fractionates with sub-pM concentration of PKA
catalytic subunit resulted in a time-dependent reduction of PDE1 activity (Figure




Differential regulation ofPDE1 and Ca /CaM-independent PDE
activities by PKA catalytic subunit
Figure 22: Cytosolic fraction ofAtT20 cells was incubated at 30°C with (shaded
symbols) or without (empty symbols) 0.2 pM PKA catalytic subunit in a
phosphorylation reaction mixture (30 mM Tris-HCl, pH 7.5, 20 mM MgSC>4, 0.5
mM ATP). Aliquots were taken from both reaction mixtures at 0, 5, 15 and 30
min for PDE assay. PDE1 activity (squares) was measured in the presence of
100 pM Ca2+/100 nM CaM and 10 pM rolipram, while Ca2+/CaM-independent
PDE activity was assayed with 0.5 mM EGTA (diamonds). Data are




Selective activation ofPDE4 activity by PKA catalytic subunit
Figure 23: Phosphorylation reactions were carried out with 0.2 pM recombinant
PKA catalytic subunit in the presence (PKA+PKI) and absence (PKA) of 0.1 pM
PKA inhibitor peptide (PKI) at 30 C for 15 min. Control reactions were
incubated without added PKA and PKI. Ca2+/CaM-independent PDE activity
was measured in the presence of 0.5 mM EGTA with (empty bar) or without




In vitro phosphorylation ofPDE1
separated by DEAE chromatography
Figure 24: (A) AtT20 peak 1 fractionates were incubated with 0.8 pM PKA
catalytic subunit in a phosphorylation buffer (30 mM Tris-HCl, pH 7.5, 20 mM
MgS04, 0.5 mM ATP) at 30 C for 5, 15, 30 and 60 min. PDE1 activity was
expressed as a percentage of control PDE1 activity at each time point incubated
without added PKA catalytic subunit. Data are mean±S.E.M., n=3. (B) AtT20
peak 1 fractionate was incubated in a phosphorylation buffer (as (A)) without any
added PKA and PKI (control), or with 1 pM PKI alone (PKI), or with 0.8 pM
PKA catalytic subunit in the absence (PKA) or presence (PKA+PKI) of 1 pM




3.3.2.2 Inhibition of CaM stimulation of PDE1 by PKA catalytic
subunit
As observed in intact cells studies, the reduction of PDE1 activity by PKA catalytic
subunit under phosphorylating conditions was due to a marked reduction to CaM
stimulation (Figure 25). Notably, the effect was greater than that observed with
CPT-cAMP and calyculin A in intact cells, resulting in a dramatic drop from about
8-fold stimulation in control to less than 1.5-fold in PKA-treated samples (Figure
25). The EC50 value for CaM stimulation was also increased more than 3-fold
(1control = 16.5±1.6 and PKA = 57.8±8.8 nM, mean±S.E.M., n=3, P<0.05, Student's
t-test), while the Hill coefficients were not significantly different (control = 1.4±0.3




PDE1 stimulation by CaM was markedly reduced
by cell-free PKA phosphorylation
Figure 25: PDE1 activity of peak 1 fractionate incubated with (empty circles) or
without (shaded circles) 0.8 pM PKA catalytic subunit for 1 hr at 30 C was
assayed with 0 to 3 pM CaM in the presence of 100 pM Ca2+. Endogenous CaM
was negligible as PDE activity measured without added CaM in the presence of
100 pM Ca2+ or 0.5 mM EGTA were the same. Data shown are duplicate PDE1
activity determinations at each CaM concentration and are representative of 3
experiments using separate peak 1 fractionates. The mean EC50 and Hill-
coefficient of CaM stimulation of the PDE1 activity obtained from these




4.1 Identification of PDE isozymes in rat adenohypophysis
The bulk (about 70%) ofPDE activity in the adenohypophysis is Ca2+/CaM-activated
i.e. PDE1 ([199, 200] and the present study). Low Km PDE1 (PDE1C) activity in rat
anterior pituitary gland has not been previously reported. The expression of PDE1C
mRNA in rat adenohypophysis could be demonstrated by RT-PCR analysis, and is in
agreement with the cAMP saturation studies which clearly indicated the presence of
both low- and high-Km PDE1 activities. As primers specific for the high-Km PDE1A
and PDE IB isozymes (but based on the mouse sequence) did not generate any RT-
PCR product, the identity of the high-Km, high-capacity PDE1 in rat
adenohypophysis remains to be clarified. Similar RT-PCR analysis with primers
specific for various PDE4 isozymes indicated the expression of PDE4B and
PDE4D3. As only primers specific for PDE4A5 and PDE4D3 splice variants were
used, the expression of other splice variants from these two subfamilies could not be
accessed in this study. Although the RT-PCR analysis was not exhaustive, it clearly
indicated the potential for differential hydrolysis of cyclic nucleotides in anterior
pituitary cells. As corticotrophs constitute only about 10% of the anterior pituitary
cells, further analysis employing in situ hybridisation and/or immunocytochemistry
will be required to clarify the expression of these PDE isotypes within the various
types of hormone secreting cells in adenohypophysis.
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4.2 Identification of PDE isozymes in AtT20 cells
Similarly to the adenohypophysis, AtT20 cells were found to express substantial
PDE1C and PDE4 activities. This conclusion is based on the use of various
previously reported family-selective PDE inhibitor compounds (see [31] for a
review), the kinetic analysis of cAMP hydrolysis, the chromatographic separation of
cAMP-hydrolysing PDE activities, the RT-PCR analysis and the regulation of the
PDE activities by activation of cAMP pathway.
RT-PCR analysis clearly indicated the expression of multiple isozymes from the
PDE1 and PDE4 families. Sequences obtained from the RT-PCR products
confirmed the expression of PDE1B, PDE1C4/5, PDE4A5, PDE4B and PDE4D3 in
AtT20 cells. The expression of these PDE isozymes could be correlated with the
results obtained from the functional characterisation of cAMP hydrolysis in AtT20
cells. Pharmacological studies using PDE family-selective inhibitors, have indicated
the predominance of PDE 1 (inhibited by 8-MIX) and PDE4 (inhibited by rolipram)
activity in AtT20 cells. This is further supported by the DEAE chromatographic
separation of cAMP-hydrolysing PDE activity, which generated two major peaks
that correspond to PDE1 (activated by Ca2+/CaM) and PDE4 (rolipram-sensitive). It
is of note that 30-40% of the cAMP-hydrolysing activity measured under Ca2+-free
conditions in AtT20 cytosol was resistant to rolipram. This PDE activity could be
due to basal PDE1 activity and/or other PDEs, as it could be inhibited fully by the
non-selective PDE inhibitor, IBMX. The previously published kinetic properties and
inhibitor profiles of PDE1C isozymes, such as low Km values for cAMP of about 1
pM and the relative resistance to vinpocetine inhibition when compared with the
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PDE1A and PDE1B isozymes [49, 84], correspond well to the properties of the low
Km PDE1 activity found in AtT20 cells. The high Km PDE1 activity apparent in two
(out of five) substrate saturation experiments using peak 1 ofDEAE chromatography
could correspond to PDE1A and/or PDE1B. Immunoprecipitation with a PDE4D-
specific monoclonal antibody, M3S1, indicated that more than half of the total PDE4
activity in AtT20 cytosolic fraction was attributable to PDE4D isozyme. The
remaining PDE4 activity could be due to at least two other PDE4 isozymes, PDE4A5
and PDE4B, which were detected by RT-PCR. In fact, a polyclonal antibody
specific for PDE4A, AC55, was found to immunoprecipitate about 24% of the total
cytosolic PDE4 activity. Subsequent immunoblotting of the M3S1
immunoprecipitates using a polyclonal PDE4D antibody, Ab313, for detection
identified two distinct immunoreactive bands of 93 and 101 kDa, the former co-
migrated with the recombinant rat PDE4D3. Furthermore, M3S1
immunoprecipitates from CPT-cAMP-treated cells indicated a mobility shift of the
93 kDa band (to 97 kDa) which is characteristic of the effect of PKA
phosphorylation on PDE4D3 [110]. Notably, PDE4D3 is the only PDE4 isozyme
that has been shown to be rapidly activated by cAMP-dependent phosphorylation
[110]. Thus the 93 kDa band in AtT20 cells corresponds to the mouse PDE4D3
isozyme. Although there is no doubt that the 101 kDa protein is a PDE4D variant (as
it was detected by two different PDE4D selective antibodies), its exact identity is less
certain as the few reports available currently indicated different apparent molecular
weights for the corresponding PDE4D splice variants from human [109] and rat
[220]. The observed size of human PDE4D4 and PDE4D5 were 119±2 kDa and
105±2 kDa respectively, while the rat PDE4D4 was observed to migrate at 105 kDa.
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However, judging from the relative distance between the 93 kDa and 101 kDa under
the conditions of SDS-PAGE used in this study, the 101 kDa is likely to correspond
to the mouse PDE4D5. The recent availability of antibodies specific for each of
these PDE4D splice variants [156] can be used to confirm the exact identity of these
isozymes. Thus, the PDE isozyme that has been shown most conclusively to be
expressed in AtT20 cells is PDE4D3, the expression of which was confirmed at both
the level of mRNA (by RT-PCR) and protein (by immunoprecipitation and
immunoblot). Taken together, these results indicate that multiple PDE1 and PDE4
isozymes may contribute to the degradation of cAMP in AtT20 cells, furthermore,
the PDE1C and PDE4D isozymes are likely to be the major cAMP-hydrolysing
PDEs in these cells.
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4.3 Activation of PDE4 activity by cAMP-dependent
phosphorylation in AtT20 cells
94-
Ca /CaM-independent PDE activity in AtT20 cells was transiently activated (peak
at 1-2 min) upon exposure of the cells to CRF, which parallels the time course of
cAMP levels in this system [180], However, no consistent changes of PDE 1 activity
by CRF treatment could be detected. This may be due to the high intrinsic PDE
activity in these cells, resulting in a relatively small (2-3 folds) and transient CRF-
induced cAMP elevation in the absence ofPDE inhibitors. According to a recent
proposal [39], it would appear that AtT20 cells may fall into the Class II or 'high
cycling' category of cells, where basal AC and PDE activities are high in order to
keep the cAMP level below the threshold ofPKA activation. Accordingly, treatment
ofAtT20 cells with a PDE-resistant cAMP analogue, CPT-cAMP, resulted in a rapid
94-
(as CRF treatment) but sustained activation of Ca /CaM-independent PDE activity
that was completely inhibited by 10 pM rolipram, indicated selective activation of
PDE4 activity by the cAMP pathway. Importantly, the action ofCPT-cAMP could
be blocked by H-89, indicating the activation ofPDE4 activity was mediated by
PKA. The selective activation of PDE4 activity in AtT20 cytosolic fraction by PKA
catalytic subunit was also demonstrated in a cell-free system. Collectively, these
data suggest that cAMP-dependent phosphorylation activates PDE4 activity in
AtT20 cells. This conclusion was strengthened by the immunoprecipitation and
immunoblot studies using PDE4D-specific antibodies, M3S1 and Ab313, which
showed that CPT-cAMP activated PDE4 activity could be largely attributed to the
PDE4D subtype and demonstrated the characteristic PKA phosphorylation-induced
mobility shift ofPDE4D3 in AtT20 cells. Interestingly, the migration of the 101 kDa
PDE4D band (pausibly PDE4D5) was also retarded upon CPT-cAMP treatment
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(albeit to a lesser extent; a 2 kDa shift compared to that of 4-5 kDa shift in PDE4D3)
to 103 kDa. Notably, investigators have been puzzled why only PDE4D3 was
observed to be phosphorylated by PKA and not PDE4D4 [114], which similarly to
PDE4D5, is a long PDE4D splice variant and contains the PKA phosphorylation site
within the RRES motif which corresponds to Ser54 in PDE4D3 [57]. Thus,
importantly, the results observed here with the 101 kDa PDE4D band in AtT20 cells
suggested that a PDE4D splice variant longer than PDE4D3 could indeed be
phosphorylated by PKA in intact cells. In line with this observation, evidence from a
recent report has indicated that PDE4D5 is also regulated by PKA phosphorylation
[234], It is of note that several long PDE4 isozymes from the other subfamily, such
as PDE4A4, PDE4C1 and PDE4B2, also contain this PKA phosphorylation motif
and their regulation by PKA remains to be studied [55],
It is of note that PKA-dependent phosphorylation may not be the only route of
activating PDE4 activity in AtT20 cells as the inhibition of protein phosphatases
1/2A by calyculin A also activated cytosolic PDE4 activity ([204] and the present
study), but this effect was only partially blocked by H-89 and appeared to be additive
with that ofCPT-cAMP at submaximal stimulation. The activation of PDE4
activity/isozymes by other protein kinases is known [235-238]. Indeed, PDE4D3
and PDE4D5 have been recently reported to be directly phosphorylated by the
extracellular receptor stimulated kinase, ERK2, at a site (Ser579 of HSPDE4D3)
towards the C-terminal end of the catalytic domain [239], Most interestingly, ERK2
phosphorylation resulted in an inhibition of the catalytic activity, indicating that
PDE4D3 activity in vivo may be a balance between PKA and ERK2 phosphorylation
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[239]. The immunoprecipitation studies with M3S1 have shown that PDE4D activity
in AtT20 cells was also activated by calyculin A, indicating that the activation of
PDE4D by phosphorylation may be reversed through protein phosphatase 1/2A. The
multiple immunoreactive bands in M3S1 immunoprecipitate obtained with calyculin
A treatment could then represent different phosphorylation/hyperphosphorylation
species by PKA (where several other potential phosphorylation sites are known to
exist [57]) and/or other protein kinases such as ERK2 [239]. The physiological
relevance of these phosphorylation events awaits further study. The activation of
PDE4D3 activity by another protein phosphatase 1/2A inhibitor, okadaic acid, which
potentiated thyroid-stimulating hormone (TSH) stimulation, has also been reported
[240]. Importantly, the effect of calyculin A treatment indicated that the
phosphorylation and activation ofPDE4D3 in the cell is rapidly reversible.
Furthermore, the regulation of recombinant HSPDE4D3 expressed in HEK293 cells
by CPT-cAMP and calyculin A was similar to that observed with AtT20 endogenous
PDE4D3. These results show that PDE4D3 activity may be regulated by multiple
kinases in many cell types, and thus function as an important target for integrating
signals from other signalling pathways.
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4.4 Inhibition of PDE1 activity by cAMP-dependent
phosphorylation in AtT20 cells
In contrast to PDE4, PDE1 activity was reduced upon activation of the cAMP
cascade in AtT20 cells. Importantly, this is the first demonstration that PDE1
activity could be rapidly regulated in intact cells, pausibly by PKA phosphorylation.
The biochemical properties of the PDE1 activity in AtT20 cells were very similar to
those previously reported for PDE1C; such as low Km for cAMP of about 1 pM and
relatively resistant to vinpocetine inhibition [83, 84], Moreover, the expression of
PDE1C4/5 mRNA was confirmed by RT-PCR. The reduction of this low Km PDE1
activity in AtT20 cells by CPT-cAMP/calyculin A could be blocked by H-89,
indicating the predominant involvement of PKA. Furthermore, the effects of CPT-
cAMP/calyculin A on PDE1 could be reproduced by incubating the cytosolic
extracts or the DEAE-cellulose chromatography peak 1 fractions (containing the low
Km PDE1 activity) with PKA catalytic subunit under phosphorylating conditions.
Importantly, the reduction of the PDE1 activity by PKA activation in AtT20 cells
was more prominent in the presence of calyculin A, suggesting rapid reversal of
PKA-mediated inhibition by protein phosphatase 1/2A in intact cells. Thus it is
reasonable to propose that PKA activation leads to an inhibition of PDE1C activity
and that this can be rapidly reversed by protein phosphatase 1 or 2A in intact cells.
The inhibition of PDE1 activity by PKA in intact cells as well as cell-free extracts
was associated with a marked reduction of the maximal stimulation of cAMP
hydrolysis by Ca2+/CaM and an increase in the apparent EC50 for CaM.
Interestingly, the former effect (a marked reduction in Vmax ofCaM-stimulated PDE1
activity) is in contrast to the reported in vitro effect of PKA phosphorylation of
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PDE1A [69, 92] and of CaM kinase II phosphorylation of PDE1B [93], where the
phosphorylated PDE1 activity could be restored to control levels (i.e. Vmax
restorable) by applying high concentrations of Ca2+/CaM which were comparable to
those used in the present study. It is of note that there are differences in the amino
acid sequence between PDE1A, PDE1B, and PDE1C isozymes at the N-terminal
region that contains the putative CaM binding and phosphorylation sites which may
account for the different effects of phosphorylation on CaM stimulation of these
isozymes (Figure 26). To date, two putative CaM binding sites have been identified
in PDE1A using limited proteolysis, deletion mutation and synthetic peptide
analyses, and both sites have been shown to be important for maximum stimulation
by CaM [56, 64], While the second (more recently identified) putative CaM binding
site (that corresponds to amino-terminal residues 98-121 of PDE1A1 [56]) is highly
conserved among members from the three PDE1 gene subfamilies, the first (initially
identified) putative CaM binding site (residues 23-41 of PDE1A2 [64]) is highly
divergent among PDE1 isozymes, particularly between the PDE1 subfamilies (Figure
26). It is tempting to speculate that variations in the first CaM binding region among
PDE1 isozymes may account for the differences in their regulation by CaM and their
sensitivities toward CaM stimulation. Indeed, a well established example is the
observation that the PDE1A1 isozyme, which differs from PDE1A2 only in the first
18 amino-terminal residues that constitute part of the first putative CaM binding site,
has an EC50 value for CaM 10-fold less than that of PDE1A2 [56, 67-69]. Amino-
terminal sequence comparison among PDE1 isozymes reveals three notable features
unique to PDE1C isozymes that are not found in the PDE1A and PDE1B isozymes
identified so far (Figure 26). Firstly, there is a 9 amino acid insertion (residues 34-42
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of MMPDE1C5) within the first putative CaM binding site. Secondly, there is a
consensus PKA phosphorylation site, RLRS (residues 43-46 ofMMPDE1C5) within
the first putative CaM binding domain. Thirdly, in addition to having the two
characterised PICA phosphorylation sites (Serl20 and Serl38 of PDE1A2 [92]) with
slight differences, there is an additional PKA phosphorylation site, RRTS (residues
145-148 of MMPDE1C5), at a position right after the "Serl38 of PDE1A2" in
PDE1C isozymes. With these unique features of PDE1C in mind, several possible
explanations can be put forward to account for the difference in the effect PKA
phosphorylation on the Vmax of CaM-stimulated PDE1A activity [69, 92] and that of
CaM-stimulated pausibly PDE1C activity in AtT20 cells reported here. The
presence of additional PKA phosphorylation sites at both putative CaM binding sites
ofPDE1C may result in a complete blockage of CaM binding/stimulation upon PKA
phosphorylation, whereas in PDE1A (and possibly PDE1B), the first CaM binding
site may still be available for CaM stimulation and thus the observed restoration of
Vmax by increasing CaM concentrations. Alternatively, the 9-amino acid insert in
PDE1C within the first putative CaM binding region may alter its property toward
CaM stimulation, and in the extreme case of not binding CaM at all, there may be
only one functional CaM binding site in PDE1C. On the other hand, the additional
PKA phosphorylation at Serl48 of MMPDE1C5 may also result in a complete
blockage of CaM binding/stimulation as opposed to PKA phosphorylation at Serl20
and Serl38 of PDE1A2 which decreases its sensitivity to CaM stimulation. Further
experiments with recombinantly expressed and purified PDE1C should shed light on
this issue. Nevertheless, there are many reports showing mutually exclusive actions
of CaM and phosphorylation on CaM-regulated enzymes, where the phosphorylated
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enzymes no longer bind to or stimulated by CaM, and vice versa, the CaM-bound
enzymes are resistant to phosphorylation [241-244], In fact, the in vitro studies with
PDE1A and PDE1B did show that in the presence of excess Ca2+/CaM,
phosphorylation was blocked [69], It is interesting to speculate that the regulation of
CaM-stimulated enzymes governed by this antagonistic mechanism will not only
depend on the immediate signals (PKA activity versus Ca2+/CaM availability) but






4.5 Differential regulation of PDE1 and PDE4 by cAMP-
dependent phosphorylation: Potential role in the control of
ACTH secretion
The induction of cAMP synthesis by CRF produces an increase in intracellular free
Ca2+, which on the one hand triggers hormone secretion, and on the other provides a
feedback inhibitory signal geared to turn off the cAMP signal and restore the resting
state [162], The Ca2+-dependent reduction of the cellular response to cAMP-
generating agonists (such as CRF) by glucocorticoid-induced proteins appears to act
through the amplification of this Ca2+ feedback [162], Processes mediating the Ca2+
feedback signal includes the inhibition of AC9 and the enhancement of Ca2+-
activated K+-currents that repolarise the membrane potential [162], The
2"bcharacterization of substantial Ca /CaM-stimulated PDE activity in rat anterior
pituitary and AtT20 cells presented in this thesis, indicated that PDE1 could serve as
• • ? I
an additional target for the Ca feedback on cAMP pathway. The PDE4D3 isozyme
is likely to play a role in the rapid negative feedback of agonist-induced cAMP
elevation in corticotrophs, which is supported by in vitro and in vivo
pharmacological studies [202, 203]. In addition, the potential inactivation of
PDE4D3 activity by ERK2 phosphorylation [239] may be involved in the
potentiation of CRF action by the other ACTH secretagogues, such as AVP and All,
which signal through the IP3/PKC pathway [160], where ERK2 is a potential
downstream target. It has been shown that activation of the cAMP cascade by CRF
opposes the inhibitory actions of glucocorticoids by blocking glucocorticoid control
of gene expression [182] and by reducing the transcription of the Type II
glucocorticoid receptor gene [245], The tendency of cAMP-dependent
i
phosphorylation to shunt cAMP hydrolysis towards the Ca /CaM-independent
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PDE4 pathway is yet a further aspect of the CRF-induced cAMP signal to by-pass





This thesis has characterised the expression of multiple PDE isozymes from the
PDE1 and PDE4 families in AtT20 cells and the adenohypophysis. In AtT20 cells,
evidence were obtained for the expression of PDE IB, PDE1C4/5, PDE4A5,
PDE4B, PDE4D3 at the mRNA level, while that of PDE4D3 and a 101 kDa PDE4D
splice variant (pausibly PDE4D5) were detected at the protein level with two
PDE4D-specific antibodies. Importantly, the PDE1C and PDE4D isozymes were
shown to be rapidly and differentially regulated by PKA-dependent phosphorylation
in vitro and in intact AtT20 cells. This differential regulation by PKA
phosphorylation was also shown to be reversible by protein phosphatase 1/2A in
intact cells. This regulatory mechanism may function as a switch between
Ca2+/CaM-dependent (through PDE1C) and Ca2+/CaM-independent (through
PDE4D) mode of cAMP hydrolysis, that contributes to the integration of signals
from ACTH secretagogues and glucocorticoids in the regulation of ACTH secretion.
In view of the wide occurrence and potential co-existence of these two PDE





1. The unique properties of PDE1C among other PDEs, its high affinity for both
cAMP and cGMP, a wide dynamic range of activity stimulated by Ca2+/CaM,
and the potential of regulation by PKA phosphorylation demonstrated in this
thesis, strongly implicate an important role in the modulation and integration of
multiple signal transduction pathways. The regulation by PKA phosphorylation
should be verified with both the recombinant enzyme and the endogenous
enzymes with PDElC-specific antibodies. The PDE1C isozymes are expressed
in many tissues [49], and the elucidation of its physiological role will prove to be
fruitful and important to further our understanding of the interaction between
9_L
Ca and cyclic nucleotide signalling.
2. The cAMP-specific rolipram-sensitive PDE4s are perhaps the most widely
expressed phosphodiesterases. Apart from having similar kinetic properties, the
multiple isozymes/splice variants of the PDE4 family are distinct in terms of
regulation, tissue/cell distribution, subcellular localisation, and function. Indeed,
regulation by different phosphorylation events and the subcellular localisation of
PDE4s are currently under intense investigation. The functional significance of
these phenomenons may be in the contribution to the localisation of cAMP
pool/signalling [146-148], and also to the assembly of signal transduction
complex [28, 247]. Current observations indicate a complex relationship
between PDE4 interaction with other proteins, phosphorylation, and inhibition by
selective inhibitors, and the physiological relevance of these regulation is also
under intense investigation. The understanding of the regulatory mechanisms
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governing the functions of different isozymes is bound to have a major impact
both in our understanding of the role of PDE4s in signal transduction and in the
development of therapeutics.
3. It would be important to access the functional roles of PDE1 and PDE4 in the
regulation of cAMP levels and ACTH secretion in corticotrophs. If PDE1 is a
major target of glucocorticoid feedback inhibition of CRF-induced ACTH
secretion, its inhibition by a selective inhibitor should markedly attenuate this
feedback action. The awaited development of more selective cell permeable
PDE1 inhibitor will facilitate such study with intact cells. Alternatively, anti-
sense approach to block PDE1 expression could also be used.
4. In recent years, we have accumulated extensive knowledge concerning the
regulation of the activity of the different PDE isozymes through indirect (cAMP
levels) assessment or in vitro (broken cell) system measurement. PDE assay with
cell extracts is carried out in an environment that can be very different compared
to intracellular conditions. Important factors such as concentrations and
spatiotemporal distribution of enzymes, substrates and regulators, within a cell
will determine the physiological relevance of potential regulation. A revolution
in the field would be the development of technology/technique to assess the
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Involvement of calyculin A inhibitable protein phosphatases in
the cyclic AMP signal transduction pathway of mouse
corticotroph tumour (AtT20) cells
'A. Antaraki, K. L. Ang & 2F. A. Antoni
MRC Brain Metabolism Unit. Department of Pharmacology, University of Edinburgh, 1 George Sq, Edinburgh. EH8 9JZ,
Scotland
1 The role of non-calcineurin protein phosphatases in the cyclic AMP signal transduction pathway was
examined in mouse pituitary corticotroph tumour (AtT20) cells.
2 Blockers of protein phosphatases, calyculin A and okadaic acid, were applied in AtT20 cells depleted
of rapidly mobilizable pools of intracellular calcium and activated by various cyclic AMP generating
agonists. Inhibitors of cyclic nucleotide phosphodiesterases were present throughout. The accumulation
of cyclic AMP was monitored by radioimmunoassay, phosphodiesterase activity in cell homogenates was
measured by radiometric assay.
3 Neither calyculin A nor okadaic acid altered basal cyclic AMP levels but cyclic AMP formation
induced by 41 amino acid residue corticotrophin releasing-factor (CRF) was strongly inhibited (up to
80%). 1-Norokadaone was inactive. Similar data were also obtained when isoprenaline or pituitary
adenylate cyclase activating peptide, 38 were used as agonists.
4 Pertussis toxin did not modify the inhibition of CRF-induced cyclic AMP production by calyculin A.
5 Pretreatment with calyculin A completely prevented the stimulation of cyclic AMP formation by
cholera toxin even in the presence of 0.5 mM isobutylmethylxanthine (IBMX) and 0.1 mM rolipram.
Cholera toxin mediated ADP-ribosylation of the 45K and 52K molecular weight Gs, isoforms
in membranes from calyculin A-pretreated cells was enhanced to 150-200% when compared with
controls.
6 Cholera toxin-induced cyclic AMP was reduced by calyculin A within 10 min when calyculin A was
applied after a 90 min pretreatment with cholera toxin. Under these conditions the effect of calyculin A
could be blocked by the combination of 0.5 mM IBMX and 0.1 mM rolipram, but not by 0.5 mM IBMX
alone.
7 Phosphodiesterase activity in AtT20 cell homogenates showed a significant, 2.7 fold increase after
treatment with calyculin A. In control cells phosphodiesterase activity was blocked by 80% in the
presence of IBMX (0.5 mM), or IBMX plus rolipram (0.1 mM). In calyculin A-treated cells
phosphodiesterase activity was also strongly inhibited by IBMX, but because of the stimulating effect
of calyculin A, the activity remaining was still 55% of that found in control homogenates. This activity
was reduced to 5% of control by using IBMX and rolipram in combination. Assay of phosphodiesterase
in Ca2' free conditions showed that calyculin A markedly increases the activity of rolipram sensitive
(type 4) phosphodiesterase.
8 Taken together, blockers of protein phosphatases (PPases) impaired signal transduction through Gs-
mediated pathways and activated cyclic AMP degrading phosphodiesterase(s), indicating that PPases 1
and/or 2A are essential for agonist-mediated regulation of cyclic AMP levels in AtT20 cells, and are thus
important in maintaining the secretory phenotype of the cells.
Keywords: Protein phosphatase; calyculin A; okadaic acid; G proteins; corticotrophin releasing factor; pituitary tumour;
phosphodiesterase; rolipram; cyclic AMP; FK506
Introduction
Protein phosphatases (PPase) are essential elements of cellular
control (Cohen, 1989). However, knowledge about their role in
the generation of the cyclic AMP response to agonists is largely
limited to the control of cell surface receptor recycling (Sibley
et al., 1987; Pitcher et al., 1995). It is generally accepted that in
addition to receptors, G proteins (Houslay. 1994), as well as
adenylyl cyclases (Jacobowitz & Iyengar, 1994; Kawabe et al.,
1994) arc substrates for protein kinases. Hence the state of
phosphorylation of these signal-transducing proteins is likely
to be influenced by protein phosphatases. Previous work in S49
lymphoma cells (Clark et al., 1993) and AtT20 corticotrope
tumour cells (Koch & Lutz-Bucher. 1994) has indicated a role
'Present address: Department of Experimental Physiology, Medical
School, University of Athens, GR 115 27 Athens, Greece.
"Author for correspondence.
for PPases in receptor-stimulated cyclic AMP production,
which was apparently distinct from the control of cell-surface
receptors.
One of the most prominent PPases. PPase 1, is under the
control of inhibitor-1 and DARPP-32 (Klee & Cohen, 1988).
These are closely related regulatory phosphoproteins which in
the phosphorylated form inhibit PPase 1. The inhibition is
relieved upon dephosphorylation of the regulatory protein by
the Ca2' /calmodulin-activated protein phosphatase calci-
neurin (Klee & Cohen, 1988). The latter mechanism provides
for a functionally co-ordinated PPase (calcineurin-PPasc 1)
cascade opposing the actions of protein kinases (Cohen. 1989).
Calcineurin-PPase 1 cascades are thought to operate in a
number of functionally important systems, such as regulation
of glycogenolysis in skeletal muscle (Klee & Cohen, 1988) ion
transport in kidney tubule cells (Aperia et al., 1992) and hip-
pocampal long-term depression (Mulkey et al., 1994).
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Previous work (Antoni et aL, 1995) in mouse pituitary
corticotrope tumour (AtT20) cells has shown that calcineurin
inhibits the formation of cyclic AMP induced by the poly¬
peptide hormone 41 amino acid residue corticotrophin re-
leasing-factor (CRF). The present study investigated whether
the control of adenosine 3':5' cyclic monophosphate (cyclic
AMP) accumulation by calcineurin involves the operation of a
calcineurin-PPase 1 cascade in this system. The data showed
that inhibitors of PPase 1/2A abolish the regulation of cyclic
AMP levels by Ca2! /calcineurin. This is nominally consistent
with the operation of a PPase cascade. However, there was also
a marked reduction of agonist-induced cyclic AMP responses.
Furthermore, PPase blockers were also effective in Ca2+ de¬
pleted cells, where calcineurin is inactive, clearly demonstrat¬
ing multiple sites of action of PPase 1/2A in the cyclic AMP
signal transduction cascade. Overall, the results suggest that
PPasc 1/2A operate in a functionally co-ordinated manner to
maintain the responsiveness of AtT20 cells to receptors cou¬
pling to Gs.
A preliminary account of this work has been published
(Antaraki & Antoni, 1994).
Methods
Cells
Mouse pituitary corticotroph tumour (AtT20 D16:16) cells
(passage 18 -35) were maintained as previously described
(Woods et al., 1992).
Measurement of cyclic AMP formation
The protocol for experiments with forskolin and agonists of G
protein-coupled receptors has been described previously (An¬
toni et ah, 1995). Briefly, cells in 24-well tissue culture plates
were washed free of serum and incubated at 37 C in Hank's
balanced salt solution without Ca21 and Mg2' (HBSS, Fife
Technologies, Paisley. U.K.). supplemented with 25 mvi
HEPES pH 7.4, 2 mM CaCk 1 mM MgS04 and bovine serum
albumin (0.25% w/v).
Thirty to forty five minutes later the medium was re¬
placed with fresh medium containing inhibitors of PPases
and cyclic nucleotide phosphodiesterases (PDE). Important¬
ly. in all experiments except for those shown in Figure lb. a
Ca2 -depleting medium was applied at this stage (HBSS.
supplemented with 25 mM HEPES pH 7.4, 2 mM NaEGTA,
1 mM MgS04, 5 pM A23187, 5 pM nimodipine and bovine
serum albumin (0.25% w/v)), and unless otherwise indicated,
this medium was used in the rest of the experiment. These
conditions were necessary in order to eliminate Ca2' -de¬
pendent regulation of cyclic AMP production (Antoni et al.,
1995). In cases where, after preincubation in Ca2+-depleting
conditions. CaCF was introduced with the CRF-stimulus to
reach 2 mM free extracellular CaCk the pH of the added
CRF containing medium was buffered as required to
maintain pH 7.4 during the test stimulation. Because of the
intensive degradation of cyclic AMP by cyclic nucleotide
phosphodiesterase in AtT20 cells (Woods et a!., 1992;
Koch & Lutz-Bucher, 1995) 0.5 mM isobutylmethylxanthine
(IBMX) was always added to the cells at this stage. In some
experiments rolipram, a highly selective blocker of type 4
PDE (Beavo & Rcifsnydcr, 1990) (courtesy of Schering,
A.G.. Berlin, F.R.G.). was also included with IBMX as in¬
dicated in the figure legends.
The cells were incubated for a further 30 min at 37 C,
then cooled to 24 C for 5 min. after which time inducers of
cyclic AMP formation were added at 24 C for 10 min (ex¬
cept for time-course studies). This protocol was used because
pilot studies had shown calyculin A to be fully effective
within 5 min at 37 C, while having no appreciable effect
within 30 min at 24 C. Test incubations were carried out at
24°C. because the effects of calcium ions and calcineurin
inhibitors were greater under these conditions (Antoni et al..
1995). Note, however, that as cholera toxin action required
incubations at 37 C, all experiments with cholera toxin and
the analysis of the time-course of calyculin A action in cells
pre-activated by CRF (Figures 4 and 6) were carried out at
37 C.
The 10 min test incubation with agonists was terminated by
adding HC1 to reach a final concentration of 0.1 mM, and
cyclic AMP was quantified by direct radioimmunoassay
(Brooker et al.. 1979). Under the conditions used 90% of the
immunoreactive cyclic AMP was intracellular.
Experiments with cholera toxin
Where intact cells were used, all incubations were carried out
at 37°C, in order to ensure that ADP-ribosylation proceeded
optimally. All other procedures for cyclic AMP determination
were the same.
ADP-ribosylation was carried out in cell membranes as
previously described (Longbottom & van Heyningen, 1989).
Briefly, approximately 2.5 x 107 cells preincubated for 30 min
in Ca2" depleting medium with or without 50 nM calyculin
A, were homogenized in 20 mM Tris/HCl (pH 7.4), 1 mM
EDTA, 250 mM sucrose, 0.1 mM phenyl methyl sulphonyl
fluoride (PMSF) and 2 ium benzamidine. Homogenization
was carried out by 10 strokes of a glass-Teflon homogenizer
and the membrane fraction was separated from the crude
homogenate by sequential centrifugations at 300, 2,000,
9,800 and 35,000 xg, respectively. Protein content was mea¬
sured by the Coomassie blue method (Bradford, 1976). The
ADP ribosylation assay mixture (final volume 0.1 ml) con¬
sisted of 20 pg ml"1 pre-activated cholera toxin, 5 pM [ade-
nylate-22P]-NAD (25-35 Ci mmol"1), 200 mM K^HP04
NaH2P04 (pH 7.5). 10 mM MgCT, 2 mM EDTA, 5 mM
ATP, 0.5 mM GTP, 10 mM creatine phosphate, 50 uml"1
creatine phosphokinase, 10 mM thymidine and 10 mM iso-
niazide. The reaction was initiated by the addition of 50 pg
membrane protein. The assay mixture was incubated at 30 C
for 30 min (maximal incorporation of radioactivity under
these conditions) and the reaction was stopped by the ad¬
dition of 1 ml of 'ice-cold' 10 mM MOPS/0.13 m NaCl (pH
7.5). Subsequently, the mixture was centrifuged at 9.000 xg.
the pellet solubilized in 60 /d of 0.1% SDS. 50 mM Tris/HCl
pH 7.8, 1 mM dithiothreitol (DTT) and 10 p\ aliquots of this
mixture were applied to a 12% poiyacrylamide gel (Phar¬
macia. Milton Keynes U.K.) and electrophoresed under
denaturing conditions. The gel was stained with Coomassie
blue, dried and autoradiographed on X-ray film or in Mo¬
lecular Dynamics phosphorimager cassettes, after which the
optical densities of the radioactive bands were quantified
with the Imagequant software as supplied by the manufac¬
turer.
Measurement of cyclic nucleotide phosphodiesterase
(PDE) activity
Crude homogenates of AtT20 cells were prepared in Teflon/'
glass homogenizers in homogenizing buffer (20 mM Tris/HCl
(pH 8), 1 mM EDTA, 0.2 mM EGTA, 50 mM NaF, 10 mM
sodium pyrophosphate, 50 mM benzamidine, 2 mM PMSF,
0.5 pg ml 1 leupeptin. 0.7 pg ml"' pepstatin, 4 pg ml"1
aprotinin and 10 pg ml"' soybean trypsin inhibitor) 50 pi/106
cells, in order to minimize proteolytic cleavage and depho-
sphorylation (Sette et al.. 1994) of PDE. The radiometric assay
of PDE activity was by column chromatography (Manganiello
& Vaughan, 1973; Kono, 1988) or a co-precipitation/filtration
assay (Schilling et al.. 1994) which gave comparable results.
The PDE assay reaction (250 p\) contained 100 mM TES-HC1
pH 7.5, 5 mM MgS04, 1 or 10 pM substrate cyclic AMP, [3H]-
cyclic AMP (NET-275. NEN. Dupont) in tracer amounts, and
50 //I of homogenate. In some experiments, 0.5 mM EGTA was
also included to reduce Ca2"-dependent PDE activity to a
minimum.
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In experiments with PDE inhibitors and calyculin A, the
requisite compounds were added to intact cells in order to
reproduce the conditions of cyclic AMP experiments as closely
as possible. PDE blockers were also added at the requisite
concentrations into the PDE assay. The PDE reaction was
terminated when it was linear both with respect to time and the
amount of homogenate protein added, (5—10 /tg or 80-
100 ng/assay point, at 1 or 10 pM substrate cyclic AMP, re¬
spectively), so that quantitative comparisons between treat¬
ment groups could be made.
Reagents
Unless otherwise specified, all reagents were from Sigma Ltd
(Poole, Dorset, U.K.). Sources of other materials were as
follows: phorbol 12,13 dibutyrate ester (PdBu), calyculin A
and okadaic acid, LC-Labs Boston (dissolved at 5 mM in
ethanol and stored at — 40°C); rat corticotrophin releasing-
factor,_41 (CRF) Bachem U.K. (Saffron Walden, Essex, U.K.);
pituitary adenylate cyclase activating peptide,. 38 (PACAP)
Peninsula Laboratories, (St Helen, Merseyside, U.K.), A23187
(Calbiochem-Novabiochem, Nottingham, U.K.); nimodipine
Semat Ltd (St Albans, Herts, U.K.); pertussis toxin (List La¬
boratories). FK506 (tacrolimus), courtesy of Fujisawa
GMBH, Munchen.
Data analysis
Student's t test and analysis of variance were used where ap¬
propriate and are indicated in the figure legends.
Results
Actions of okadaic acid and calyculin A on receptor-
induced cyclic AMP formation
Pilot studies showed that in cells treated with IBMX, both
calyculin A (Figure la) and okadaic acid (not shown) in¬
hibited CRF-induced cyclic AMP formation irrespective of
the calcium status of the cells. Notably, in the presence of
maximally effective concentrations of calyculin A, the en¬
hancement of cyclic AMP formation by Ca2+-depletion was
no longer apparent. Furthermore, the enhancement of the
cyclic AMP response by the calcineurin blocker FK506
(Antoni et al., 1995) could not be observed in the presence
of calyculin A (Figure lb). On the one hand, these data are
compatible with the PPase cascade hypothesis, i.e. the serial
coupling of calcineurin and PPase 1, although the marked
reduction of the cyclic AMP response complicates the in¬
terpretation of the data. On the other hand, the effects ob¬
served in Ca2 +-depleted cells clearly indicate that type 1/2A
PPases are involved in the control of cyclic AMP accumu¬
lation independently of Ca2 +calcineurin. In order to examine
this problem further, the subsequent studies were carried out
in Ca2 +-depleted cells.
Under these conditions inhibition of CRF-induced cyclic
AMP accumulation by 100 nM calyculin A was evident at all
time-points examined after the addition of CRF (Figure 2a).
Unless otherwise indicated, all reactions were terminated at
10 min. The reduction of cyclic AMP accumulation by 100 nM
calyculin A was observed at all concentrations of CRF that
caused a significant enhancement of cyclic AMP production
(Figure 2b).
The dose-response curves for okadaic acid and calyculin A
revealed that okadaic acid was approximately 80 fold less
potent than calyculin A in reducing CRF-induced cyclic AMP
formation, moreover 1-norokadaone, an okadaic acid analo¬
gue that is not bound by PPases (Nishiwaki et al., 1990), had
no effect on cyclic AMP formation (Figure 2c).
Similar data were obtained with the /(-adrenoceptor agonist
isoprenaline, that activates a f adrenoceptor (Heisler et al.,
1983) in AtT20 cells, and PACAP (Figure 2d).
Lack of involvement of pertussis toxin sensitive G-
proteins
The half-effective concentration and the maximal effect of ca¬
lyculin A with respect to CRF-induced cyclic AMP formation
was not altered by preincubation of the cells with pertussis
toxin (1 pg mL1 18 h) (Figure 3a).
The same PTX treatment markedly attenuated the inhibi¬
tory effect of 10 nM somatostatin (Antoni et al., 1995), a
peptide hormone known to reduce cyclic AMP formation




















Figure 1 (a) Inhibition of cyclic AMP accumulation in response to
10 nM CRF by 50 nM calyculin A in (A) Ca2 1 -depleted cells and
(O) Ca2 +-depleted cells repleted with Ca24 at the time of addition of
CRF (see Methods); 0.5 mM IBMX and calyculin A were added
30 min before CRF. Basal levels of cyclic AMP were 0.65 + 0.002 and
0.54+ 0.02 pmol/well (mean±s.e.mean) in the Ca2 + -depleted and
Ca2' -repleted groups, respectively, (b) Blockade of calcineurin
modulation of 10 nM CRF-induced cyclic AMP by calyculin A in
AtT20 cells incubated in medium containing 2 mM CaCL (without
ionophore) throughout the course of the experiment. All groups of
cells were preincubated with 0.5 mM IBMX, and the indicated
combinations of vehicle (0.4% ethanol), 50 nM calyculin A and 2 pM
FK506 for 30 min; open columns, control: hatched columns, FK506.
Basal cyclic AMP level was 1.6 + 0.09 pmol/well. Data are means ±
s.e.mean; /; = 4/group. *P<0.05 vs vehicle, one-way analysis of
variance followed by Newman-Keuls test.
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Cholera toxin induced cyclic AMP synthesis was blocked
by calyculin A
Pretreatment with 50 nM calyculin A completely blocked the
formation of cyclic AMP induced by cholera toxin despite the
prcsenec of IBMX (not shown and (Koch & Lutz-Bucher,
1994)) or IBMX as well as rolipram (Figure 4).
In view of the complete block of the effect of cholera toxin
by preincubation with calyculin A, the effects of calyculin A
pretreatment on ADP-ribosylation were examined. In mem¬
branes prepared from calyculin A-pretreated cells (Figure 5).
there was a clear increase (50% and 100% expressed in arbi¬
trary optical density units in experiment 1 and 2, respectively)
of [12P]-ADP ribosc incorporation into two major radiolabel¬
ed bands corresponding to the two commonly occurring 45K
and 52K molecular weight splice variants (Robishaw et al.,
1986) of G,,. No differential changes in the intensity of
radiolabelling of these bands were discernible.
In order to circumvent the apparent blockade of the acti¬
vation of Gs by calyculin A, the cells were activated by cholera
toxin for 90 min, after which PDE blockers and calyculin A
were added in sequence. Under these conditions (Figure 6a)
when only 0.5 mM IBMX was present, a marked inhibition of
cyclic AMP accumulation developed within 10 min after the
addition of 50 nM calyculin A. However, 0.5 mM IBMX and
0.1 mM rolipram in combination blocked the effect of calyculin
A at all time points, except at 30 min when a small (20%). but
statistically significant (P<0.05, one-way ANOVA followed
by Newman Keuls test) inhibition developed.
As IBMX and rolipram in combination also markedly
(close to 150%) enhanced the cyclic AMP response to cholera
toxin when compared with IBMX alone, the response to 10 nM
CRF was re-examined. This was also increased upon the ad¬
dition of 0.1 mM rolipram and 0.5 mM IBMX, but only by
20% when compared with the response observed in the pre¬
sence of 0.5 mM IBMX alone (not shown). However, the
profound inhibition by calyculin A either as preincubation
(not shown), or when given 1.5 min after the addition of CRF
(Figure 6b) prevailed even in the presence of 0.1 mM rolipram
and 0.5 ntM IBMX.
Effect of calyculin A on phosphodiesterase activity
Analysis of the time-course of calyculin A action on cholera
toxin-induced cyclic AMP formation (see Figure 6a) indicated






























Figure 2 Inhibition of CRF-induced cyclic AMP production by protein phosphatase (PPase) blockers in Ca2 + -depleted AtT20 cells
in the presence of 0.5 mM IBMX. PPase blockers and IBMX were applied 30 min before the addition of CRF. Data are means and
vertical lines show s.e.mean; ;i = 4-6/group, and representative of at least two identical experiments, (a) Time-course of cyclic AMP
formation induced by 10 nM CRF in cells treated with (□) vehicle or (■) 100 nM calyculin A. (b) Effect of (■) 100 nM calyculin A
and (□) vehicle on cyclic AMP production in response to various concentrations of CRF. the reaction was terminated 10 min after
the addition of CRF. (c) Specificity of PPAse blocker action on cyclic AMP production evoked by 10 nM CRF. Data are expressed
as percentage of the cyclic AMP response to 10 nM CRF. Basal levels of cyclic AMP were 0.79 + 0.05 pmol/well, CRF-induced
cyclic AMP taken as 100% was 11.3 + 0.4 pmol/well. Effects (A) calyculin A. (O) okadaic acid and (□) 1-nor-okadone are shown,
(d) Concentration-dependent effect of calyculin A on cyclic AMP accumulation induced by (A) 10 nM CRF, (A) PACAP or (□)
isoprenaline. All stimuli caused comparable increases (10-20 fold basal) of total cyclic AMP.








Figure 3 Effect of various concentrations of calyculin A on cyclic
AMP production induced by 10 nM CRF in calcium-depleted AtT20
cells after 18 h of treatment with (■) vehicle or (A) ' /ig mF1
pertussis toxin. Calyculin A was applied 30 min before stimulation by
CRF. IBMX (0.5 nw) was present during the addition of calyculin A
and CRF. Data arc means and vertical lines show s.e.mean; n = 4.










Figure 4 Interaction of calyculin A with cholera toxin in calcium
depleted AtT20 cells. Levels of cyclic AMP in AtT20 cells pretreated
with 0.5 mM IBMX and 0.1 mM rolipram plus vehicle (A) or 50 nM
calyculin A (■) for 30 min. Cholera toxin (125 ng ml-1) was added
at 0 min. Means + s.e.mean (vertical lines) u = 4 group, representative
of two experiments.
AtT20 cells. Measurement of PDE activity in Ca2'-depleted
cells revealed a clear stimulation of cyclic AMP hydrolysis
upon 30 min of pretreatment with 50 nM calyculin A (Figure
7a and b). Treatment with PDE blockers by use of the same
protocol as in the experiments for cyclic AMP accumulation
and also including the blockers in the PDE assay (10 //M
substrate) showed (Figure 7b) that IBMX inhibited PDE ac¬
tivity up to 80%. However, because of the marked enhance¬
ment of PDE activity in calyculin A treated cells, the activity
remaining in the presence of IBMX was 55'% of that found in
control cells. Combination of rolipram with IBMX reduced
this activity to 5% of control.
The time-course of the onset of the effect of calyculin A on
PDE activity was assayed under Ca2' free conditions at 1 /tM
substrate thus favouring detection of PDE4. A significant in¬
crease of activity was evident within 5 min of addition to the
cells (Figure 7c) and was completely blocked by addition of
10 fiM rolipram in the PDE assay (Figure 7c). Addition of




















Figure 5 Effect of pretreatment with calyculin A on cholera toxin
induced ADP-ribosylation in AtT20 cell membranes. Cells were
incubated with 0.4% (v/v) ethanol or 50 hm calyculin A in Ca2 + -
depleting medium for 30 min and membranes were reacted with
cholera toxin (CTX) in ADP-ribosylation buffer or ADP-ribosylation
buffer alone for 30 min. after which the proteins were resolved by gel
electrophoresis under denaturing conditions. Autoradiography was
carried out with X-ray film as well as phosphorimager cassettes. Data
shown are representative of two identical experiments. Control:
vehicle treated cells, membranes in ADP ribosylation buffer only,
CTX: vehicle treated cells, membranes treated with CTX: CTX +
Calyc. A: cells treated with calyculin A membranes reacted with CTX
and ADP ribosylation buffer; Calyc.A: cells treated with calyculin A,
membranes in ADP ribosylation buffer only. Quantification of the
optical densities by image analysis indicated a 2 fold increase of
incorporation into the two bands migrating approximately at 45K
and 52K molecular weight. The high molecular weight band at 97K
may be a dimer of the lower molecular weight forms.
furthermore, assays in the presence of 100 //M Ca2', 100 nM
calmodulin and 10 /tM rolipram showed no increase of PDE
activity after treatment with calyculin A (results not shown).
Collectively, these data indicate selective activation of a type 4
PDE by calyculin A.
Effects of calyculin A are not mimicked by activation of
protein kinase C
In view of the possible activation of protein kinase C by ca¬
lyculin A (Gopalakrishna et a/., 1992) the effects of phorbol
dibutyrate ester (PdBu) on CRF-induced cyclic AMP accu¬
mulation were also examined. In calcium-depleted cells pre¬
treated with 0.5 mM IBMX, 10 nM PdBu produced a
significant (P<0.0001, two-way ANOVA) 30% inhibition of
CRF-evoked cyclic AMP. which was also apparent in the
presence of a maximally effective concentration (50 nM) of
calyculin A (Figure 8). The actions of PdBu and calyculin A on
CRF-induced cyclic AMP were not additive, PdBu produced a
smaller decrement in the presence of calyculin A (P<0.01 for
interaction between PdBu and calyculin A in a linear ANOVA
model). Finally, treatment of Ca2'-depleted cells with 10 nM
PdBu for 30 min failed to alter PDE activity (not shown).
Discussion
Previous work has indicated a prominent role of PPases in
cellular responsiveness through the dephosphorylation of G-
protein coupled membrane receptors (Sibley et a/., 1987;





































Figure 6 (a) Levels of cyclic AMP in AtT20 cells pretreated for
90 min with (125 ng ml"1) cholera toxin; 0.5 mM IBMX (A, A) or
0.5 mM IBMX and 0.1 mM rolipram (O, •) were added 5 min
before vehicle (A. O) or 50 hm calyculin A (A- •) was introduced
at 0 min. Data are representative of two identical experiments, (b)
Levels of cyclic AMP in AtT20 cells pretreated with 0.5 mM IBMX
and 0.1 mM rolipram for 30 min; 10 nM CRF was added 1.5 min
before the addition of vehicle (A) or 50 ttM calyculin A (A) at 0 min.
Pitcher et al., 1995). While it is possible that some of the effects
observed in the present study are due to the depletion of cell
surface receptor pools required for a sustained response to
agonist stimulation, the data clearly show effects of PPase
blockers downstream of membrane receptors. The reduction of
agonist as well as cholera toxin-stimulated cyclic AMP
synthesis indicates impairment of the activation of adenylyl
cyclase by Gs. Moreover, a marked stimulation of cyclic AMP
phosphodiesterase activity was demonstrated which was
functionally relevant with respect to cyclic AMP accumulation.
Specificity of PPase inhibitors
The relative potencies of calyculin A and okadaic acid to in¬
hibit receptor-induced cyclic AMP formation respectively,
conform with the pharmacology of these compounds to inhibit
PPasel activity (Cohen et al., 1990). Similarly, a previous study
(Koch & Lutz-Bucher, 1994) found a 100 fold difference in the
potencies of calyculin A and okadaic acid to block CRF- and
PACAP-induced cyclic AMP production in AtT20 cells. A
close structural analogue of okadaic acid, 1-norokadaone, that
does not bind to protein phosphatases (Nishiwaki et al., 1990)
was inactive in our system. The cyclic AMP response to for-




























Figure 7 Effect of calyculin A and phosphodiesterase (PDE)
blockers on cyclic AMP phosphodiesterase activity in calcium-
depleted AtT20 cells, (a) Time-course of PDE activity in homo-
genates prepared from (A) vehicle (Veh) or (A) 50 nM calyculin A-
treated AtT20 cells with 10 /<M cyclic AMP as substrate. Individual
points from a representative experiment, (b) Cyclic AMP PDE
activity in homogenates prepared from AtT20 cells pretreated with
vehicle or 50 nM calyculin A plus 0.5 mM IBMX or 0.5 mM IBMX
and 0.1 mM rolipram (Roli) PDE blockers were also added to the
assay reaction mixture (substrate 10 gM cyclic AMP), the reactions
were terminated at 10 min. Data are means + s.e.mean, « = 4/group,
pooled from 3 separate experiments, the basal activity taken as 100%
ranged between 60 and 100 pmol mg"1 protein min"1 in these
experiments, (c) Cyclic AMP PDE activity of homogenates prepared
from AtT20 cells pretreated with 50 nM calyculin A for the indicated
time intervals. The PDE activity was assayed in the presence of (A)
0.1% (v/v) DMSO (Veh) or (A) 10/tM rolipram the assay buffer
contained 0.5 mM EGTA and 1 /tM cyclic AMP substrate.
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(Koch & Lutz-Bucher, 1994) or even enhanced (A. Antaraki, &
F.A. Antoni, unpublished data), upon treatment with PPase
blockers, which argues against an impairment of adenylyl cy¬
clase catalytic activity or a generalized toxic damage to cellular
metabolism. Finally, activation of protein kinase C with
phorbol ester did not mimic the effects of calyculin A. It is
therefore reasonable to suggest that the effects observed here
are due mainly to blockade of PPase activity, primarily types 1
and 2A, and not to non-specific interferences with other me¬
chanisms of cellular control.
Figure 8 Effect of 10 nM phorbol 12, 13 dibutyrate ester (PdBu) on
cyclic AMP accumulation induced by 10 nM CRF in Ca2 ' -depleted
AtT20 cells in the presence (hatched columns) or absence (open
columns) of a maximally effective (50 nM) concentration of calyculin
A. Cells were preincubated for 30 min with 0.5 mM IBMX and the
indicated combinations of vehicle (0.4% ethanol), calyculin A and
PdBu. Data are means ±s.e.mean, n = 4/group, representative of two
experiments. Two-way ANOVA P<0.0001 for the effects of calyculin
A and PdBu, there was also a significant interaction PcO.Ol between
the two treatments.
Blockade of modulation of cyclic AMP by Ca2* in the
presence of calyculin A
Calcium ions exert a powerful and functionally relevant ne¬
gative feedback effect on cyclic AMP formation in AtT20 cells
(Shipston et al., 1994; Antoni et al., 1995) which is interrupted
by blockers of calcineurin such as FK506. In the present study
calyculin A blocked the effects of calcium depletion and re¬
pletion previously (Antoni et al., 1995) shown to enhance and
inhibit the CRF-induced cyclic AMP response, respectively.
Accordingly, the effect of FK506 was also abolished. Nomin¬
ally, these data are consonant with the calcineurin-PPasel
cascade hypothesis (Figure 9). However, calyculin A caused a
strong net inhibition of the cyclic AMP response to activation
by Gs-coupled receptors, whereas blockers of calcineurin en¬
hanced it. Furthermore, the suppression of the cyclic AMP
response by calyculin A was also observed in Ca2+-depleted
cells. Thus, while these findings favour that calcineurin oper¬
ates through PPase 1 in AtT20 cells as proposed previously for
other systems (Klee & Cohen, 1988), it is clear that further sites
of PPase action are involved that are readily demonstrable in
cells depleted of rapidly mobilizable Ca2+.
Effects of PPase blockade on Gs mediated responses
Overall, the consequence of PPase inhibition was a marked
reduction of the rate of receptor- as well as cholera toxin-
stimulated cyclic AMP formation. Pertussis toxin sensitive G-
proteins have no apparent role in this effect of PPase blockers.
Surprisingly, despite the complete blockade of cholera
toxin-induced cyclic AMP formation by calyculin A, the ADP-
ribosylation of Gsa by cholera toxin was enhanced. As recent
work suggests that Gsa in the heterotrimeric complex with p
and y subunits is a much better substrate for cholera toxin than



















Figure 9 Schematic summary of multiple sites of PPase modulation of the cyclic AMP (cAMP) signal transduction cascade in
AtT20 cells. Arrows and T-s represent stimulation and inhibition, respectively. The broken effector lines indicate that multiple
enzymatic steps may be involved. Ca2 +-dependent modulation by PPases: the operation of a calcineurin-PPasel cascade is suggested
by the loss of Ca2+/calcineurin modulation of agonist-induced cyclic AMP synthesis by calyculin A. The respective protein kinase(s)
that appear to be facilitatory to Gs-cyclase coupling remain to be identified. The site of PPasel action is not known. Ca2 + -
independent modulation by PPases: a calyculin A-sensitive mechanism is required for efficient coupling of Gs and adenylyl cyclase
implying the existence of inhibitory phosphorylation. The site(s) of this modulation and the protein kinases are not known.
Calyculin A enhanced the activity of a rolipram-sensitive PDE, indicating constitutive stimulant phosphorylation of a PDE 4
isotype.
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could be interpreted to suggest that the probability of G„
subunit dissociation, which is a prerequisite for the activation
of adenylyl cyclase (Gilman, 1987), is reduced by calyculin A.
This hypothesis is also compatible with the observation that
after irreversible activation of G„ by cholera toxin, the prin¬
cipal mediator of calyculin A action appeared to be a rolipram/
I3MX sensitive PDE, whereas this was clearly not the case
when calyculin A was applied before cholera toxin. Blockade
of PDE with rolipram/IBMX also failed to prevent the inhi¬
bition of CRF-induced activation of adenylyl cyclase by ca¬
lyculin A, where cycling ofG„ from the activated (dissociated)
to the deactivated (heterotrimeric) state is likely to be essential
for the stimulating effect of the agonist (Gilman, 1987). In
addition, other workers have shown a drastic reduction of the
cyclic AMP response to CRF in membranes of AtT20 cells
pretreated with calyculin A (Koch & Lutz-Bucher, 1994). Thus
calyculin A interferes with the activation of adenylyl cyclase by
Gs. This implies that in AtT20 cells constitutive phosphoryla-
tion/dephosphorylation reactions regulate the coupling of Gs
to adenylyl cyclase.
Phosphorylation of G„ by a variety of protein kinase
cascades, particularly epidermal growth factor-induced ki¬
nase cascades, has been observed previously (see Houslay.
1994; Liebntan et a/., 1996 for reviews). One apparent out¬
come of G„ phosphorylation by epidermal growth factor-
induced mechanisms is the inhibition of the activation of
adenylyl cyclase by Gs-coupled receptors, which conforms
with the findings presented here. Another potential me¬
chanism that could underlie the reduction in the stimulation
of adenylyl cyclase by receptor-activated Gs is the phos¬
phorylation of adenylyl cyclase by protein kinases (Premont
et al., 1992). Adenylyl cyclase type 9 is the predominant
cyclase isotype expressed in AtT20 cells (Antoni et al., 1995;
Paterson et al., 1995), which, like other mammalian cyclase
isoforms, is potentially phosphorylated by several protein
kinases (Antoni. 1997). However, the functional relevance of
specified phosphorylation sites in adenylyl cyclases remains
to be investigated.
Effects on PDE
Calyculin A substantially (2-3 fold) enhanced cyclic AMP
hydrolysis in homogenates from calcium-depleted cells, and
this was also evident in cells incubated in normal, calcium-
containing medium (A. Antaraki. K.L. Ang & F.A. Antoni,
unpublished data) showing that the effects are not due to de¬
pletion of intracellular calcium stores.
The aim of the preliminary analysis of AtT20 cell PDE
activity presented here was to clarify the results obtained with
cholera toxin. AtT20 cells contain both Type 1 and Type 4
PDE activity (Ang & Antoni, 1996) and calyculin A specifically
increased the latter. Moreover, at 10 /(M of substrate cyclic
AMP, IBMX blocked 80% of total PDE activity while roli¬
pram caused a 40% inhibition. As PDE activity rose almost 3
fold in response to calyculin A, PDE activity was substantial,
55% of that in vehicle-treated cells, in the presence of 0.5 mM
IBMX. Combination of rolipram and IBMX in calyculin A-
treated cells produced close to complete (95%) inhibition of
PDE activity. These results can be correlated with the obser¬
vation that when cyclic AMP formation was stimulated by
cholera toxin i.e. irreversibly activated G„ the combination of
rolipram and IBMX but not IBMX alone blocked the inhibi¬
tory effect of calyculin A on cyclic AMP accumulation. Thus
under these conditions the effect of calyculin A on cyclic AMP
accumulation was largely due to activation of PDE.
These findings indicate that a large proportion of PDE ac¬
tivity in AtT20 cells is under stimulant control by constitu-
tively active protein kinase(s) and is inhibited by calyculin A
sensitive dcphosphorylation. Regulation of various PDEs by
phosphorylation is an important element of cellular control in
several types of cell (Beltman et al., 1993). Specifically, other
investigators have formed an increase of PDE activity by
okadaic acid in adipocytes (Shibata el al., 1991), and phos¬
phorylation by protein kinase A influences the activity of Type
4 PDE in a thyroid cell line (Sette et al., 1994). Moreover,
control of calmodulin activated Type 1 PDEs by phosphory¬
lation has been also shown (Sharma et al., 1988). However, the
impact of these changes on cyclic AMP signals awaits further
analysis.
Functional implications
A diagrammatic summary of the results presented in this
paper is shown in Figure 9. Taken together, the present
observations suggest that in AtT20 cells multiple phos¬
phorylations by constitutively active protein kinases block
cellular responses to cyclic AMP generating agonists. PPases
inhibited by calyculin A and okadaic acid (primarily PPase 1
with possible requirement for concomitant blockade PPase
2A) have essential and functionally consonant actions in
opposing constitutive phosphorylations and thus maintaining
the transduction of extracellular signals operating through
heterotrimeric G protein activation. AtT20 cells have been
cultured as a relatively well-differentiated secretory cell line
for almost three decades (Yasumura, 1968), while normal rat
pituitary corticotrophs and human corticotroph adenoma
cells generally dedifferentiate in similar culture conditions
within a few weeks (Westphal et a!., 1986; Childs et a/..
1989). As cyclic AMP may provide the signal for prolif¬
eration of a differentiated phenotype of endocrine cell
(Dumont et al.. 1989) the constitutively active protein ki¬
nases are likely to promote non-differentiated growth, which
is suppressed by PPases. Evidence specifically showing un¬
ique patterns of constitutional Ser/Thr phosphorylation and
a resultant increase in the activity of pp60 (c-sir) in AtT20
cells has been obtained (Gould et al.. 1989). Thus the pre¬
sent findings may help to explain the tumour promoter ac¬
tions of PPase blockers, i.e. the facilitation of proliferation
without differentiation.
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